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SUMMARY 
Endocardial endothelial cells (EECs) can exert a significant influence on 
cardiac function by releasing various factors such as nitric oxide (NO), 
prostanoids, endothelin-1 (ET-1) and angiotensin II (Ang II). Recently, results 
obtained in our laboratory demonstrated the presence of NPY and its receptors, Y] 
and Yi, as well as ET-1 and its receptors, ETA and ETB, at the level of endocardial 
endothelial cells (EECs). We have also shown that NPY induces a sustained rise in 
the intracellular calcium level of these cells, and that only right ventricular EECs 
have the capacity of secreting NPY. Moreover, the evidence in the literature has 
become plentiful about complex interactions existing between ET-1 and other 
cardioactive mediators, such as NO and Ang II. Based on the above-mentioned 
data, the objective of this study was to investigate if a dialogue equally exists 
between the systems of NPY and ET-1 at the level of human right (hREECs) and 
left (hLEECs) ventricular EECs. 
Using the technique of indirect immunofluorescence coupled to 3-D 
confocal microscopy, as well as ELISA, our results show that increasing 
concentrations of NPY (10"15, 10"10 and 10"5M) induce the release of ET-1 from 
REECs and LEECs in a time- and dose-dependent fashion. However, right 
ventricular EECs seem to have a higher ET-1 secretory capacity as compared to 
their left counterparts. Upon the use of selective antagonists for the NPY receptors, 
Y], Y2 and Y5, and the ET-1 receptors, ETA and ETB, our results demonstrated that 
in REECs the NPY-induced release of ET-1 seems to be primarily due to Y2 
receptor activation, with the subsequent activation of the ETA and ETB receptors 
by the released ET-1. On the other hand, in LEECs, the NPY-evoked secretion of 
ET-1 seems to be mainly the result of Y5 receptor activation by NPY. Unlike 
REECs, the ET-1 released by NPY in this type of cells does not seem to be 
contributing further to its own release by activation of its ETA and ETB receptors. 
Therefore, our results suggest that NPY is a regulator of ET-1 secretion at 
the level of human EECs, and that this secretory process of ET-1 is different 
between the right and left ventricular cells. Moreover, these results serve to 
highlight and endorse the important sensory and tuning roles that right and left 
ventricular EECs possess, respectively. The ability of EECs to contribute to the 
local as well as systemic release of factors, such as NPY and ET-1, can affect not 
only the excitation-secretion coupling of EECs and the excitation-contraction 
coupling of cardiomyocytes, but also the physiological and pathophysiological 
state of the underlying heart muscle. 
Keywords: Neuropeptide Y, endothelin-1, human endocardial endothelial cells, 
NPY-induced ET-1 secretion, Y2 and Y5 receptors. 
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RESUME 
Les cellules endotheliales endocardiques (CEEs) modulent la fonction 
cardiaque en liberant differents facteurs cardioactifs tels l'oxide nitrique (NO), les 
prostacyclines, l'endotheline-1 (ET-1) et 1'angiotensine II (Ang II). Recemment, 
des resultats obtenus dans notre laboratoire demontrent la presence du NPY et ses 
recepteurs Yi et Y2, ainsi que de l'ET-1 et ses recepteurs ETA et ETB, au niveau 
des cellules endotheliales endocardiques humaines (CEEs). Nous avons egalement 
demontre que le NPY induit une augmentation soutenue du calcium intracellulaire 
de ces cellules et que seulement les CEEs isolees du ventricule droit ont la capacite 
de secreter le NPY. De plus, plusieurs evidences dans la litterature montrent 
l'existence d'interactions complexes entre l'ET-1 et d'autres mediateurs 
cardioactifs comme le NO et l'Ang II. Base sur ces informations, l'objectif de 
cette etude est de determiner si un dialogue existe egalement entre les systemes du 
NPY et de l'ET-1 au niveau des CEEs humaines isolees des ventricules droit 
(CEEDs) et gauche (CEEGs). 
En utilisant la technique d'immunofluorescence indirecte couplee a la 
microscopie confocale en 3D ainsi que la technique ELISA, nos resultats montrent 
que l'application de concentrations croissantes de NPY (10"'~\ 10"10 et 10"5M) 
induit la liberation de l'ET-1 des CEEDs et des CEEGs et ce en fonction du temps 
et de la concentration. II semble que les CEEDs possedent une plus grande 
capacite de secretion de l'ET-1 par rapport aux CEEGs. L'utilisation 
d'antagonistes selectifs des recepteurs Yi, Y2 et Yj, et des recepteurs ETA et ETB, 
nous ont permis de demontrer qu'au niveau des CEEDs, la secretion de l'ET-1 
induite par le NPY est principalement due a 1'activation des recepteurs Y2. De plus, 
il semble que l'ET-1 ainsi libere active par la suite les recepteurs ETA et ETB. De 
facon differente, au niveau des CEEGs, la secretion de l'ET-1 induite par le NPY 
est due a l'activation des recepteurs Y$ sans la participation subsequente des 
recepteurs ETA et ETB dans cet effet. 
Nos resultats suggerent que le NPY agit comme un regulateur de la 
secretion de l'ET-1 au niveau des CEEs humaines et que la capacite de secretion 
de l'ET-1 par le NPY est differente au niveau des CEEDs par rapport a celle des 
CEEGs. Ces resultats suggerent egalement que les CEEs joue un role de senseur 
du NPY et que ce dernier contribue, d'une facon importante, a la regulation du 
niveau de l'ET-1 circulant arteriel et veineux. 
Mots Cles: Neuropeptide Y, endotheline-1, cellules endotheliales endocardiques 
humaines, secretion de l'ET-1 induite par le NPY, recepteurs Y2 et Y5. 
I. INTRODUCTION 
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1.1 The endocardial endothelium 
Ever since Aristotle, the heart was viewed as one of the first organs to 
acquire function in the developing embryo: "In embryos, as soon as they are 
formed, the heart can be seen moving before any of the other parts, just like a 
living creature; which shows that it is the source of their nature in all blooded 
animals" (ARISTOTLE, 1983; BRUTSAERT and ANDRIES, 1992). 
Traditionally, however, and since the elucidation of the circulatory system by 
Harvey in the early 1600s, the prevailing view of the cardiovascular system was 
that of a closed circulatory loop, consisting of a pump and a series of conduit 
vessels, the sole role of which is delivering oxygen and nutrients to the various 
tissues of the body (AIRD, 2004). Nevertheless, our insights into cardiac function 
have evolved greatly over the years so that the heart is now recognized as a 
pericellular, multifunctional organ in which the endothelium, and more 
particularly the endocardial endothelium (EE), plays a very important role 
(BRUTSAERT, 2003). The endocardia] endothelium forms a crucial part of the 
larger category known as cardiac endothelial cells (SHAH et al, 1996), which in 
their turn are a major part of endothelial cells (ECs) in general (KURUVILLA and 
KARTHA, 2003). Endothelial cells form a continuous, single-cell thick layer that 
lines the entire circulatory system (GALLEY and WEBSTER, 2004), and are 
divided into cardiac endothelial cells, lining the cavities of the heart, and vascular 
endothelial cells, lining the luminal surface of blood vessels (KURUVILLA and 
KARTHA, 2003). The former then branch into microvascular endothelial cells 
(MVEs) which line the heart capillaries, and endocardial endothelial cells (EECs) 
which cover the surface of the ventricles and atria (BRUTSAERT, 2003; 
KURUVILLA and KARTHA, 2003). 
The EE occupies a unique position in the cardiovascular system between 
the circulating blood and the underlying myocardium on the one hand, and at the 
entrance and exit of the pulmonary circulation on the other (BRUTSAERT, 2003; 
KURUVILLA and KARTHA, 2003). It is formed by the process of vasculogenesis 
and seems to be one of the earliest organs to develop and modulate cardiac 
performance (KURUVILLA and KARTHA, 2003). The endocardial endothelial 
monolayer has a thickness of ~ 0.5 urn and rests on a thin basement membrane 
consisting of a basal lamina and an underlying reticular lamina (Figure 1) 
(RHODIN, 1974; BRUTSAERT and ANDRIES, 1992; KURUVILLA and 
KARTHA, 2003). An endocardial nerve plexus, which is known to influence 
cardiac function, separates EECs from the subjacent cardiomyocytes and releases 
many peptides, the most abundant of which being NPY (MARRON et al., 1994; 
MARRON et al, 1995). EECs are somewhat larger than endothelial cells in other 
regions of the circulatory system (ANDRIES, 1994; BRUTSAERT, 2003), and are 
characterized by a well-developed golgi apparatus, endoplasmic reticulum 
(ANDRIES and BRUTSAERT, 1991; BRUTSAERT and ANDRIES, 1992) and a 
high number of tubular or round-shaped mitochondria surrounding a large nuclear 
bulge (JACQUES et al, 2003b). Weibel-Palade bodies, or endothelial-specific 
bodies, are also present in EECs (ANDRIES and BRUTSAERT, 1991). They are 
small rod-shaped structures which contain multimers of von Willebrand factor 
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(vWF) that is known for its role in hemostatic events (SPORN et ah, 1989). The 
luminal surface of EECs has a large number of microvilli, thus providing a high 
ratio of EE surface area to ventricular volume and revealing a very important 
sensory role for these cells (EDANAGA, 1975; HARASAKI et ai, 1975; PEINE 
and LOW, 1975; BRUTSAERT, 1989). In addition. EECs are characterized by 
extensive intercellular overlap at junctional areas (MELAX and LEESON, 1967; 
BRUTSAERT et ai, 1998). These intercellular clefts usually contain one or two 
tight junctions which serve as a selective barrier to small molecules and a total 
barrier to large macromolecules (BRUTSAERT and ANDRIES, 1992; 
BRUTSAERT, 2003). Some of these clefts are free of junctions (ANVERSA et 
ai, 1975) thus representing the main route of transendothelial transport of 
macromolecules across the endocardial layer (KURUVILLA and KARTHA, 
2003). Moreover, one of the most important features of the EE is the abundance of 
gap junctions that connect the different cells, allow for rapid intercellular 
electrochemical coupling and add further solid support to the sensory role of EECs 
(BRUTSAERT ef ai, 1996; BENY, 1999). 
1.1.1 Crosstalk between the endocardial endothelium and the underlying 
myocardium 
Both EECs and VECs are known to be modulators of cardiac performance 
(KURUVILLA and KARTHA, 2003). But despite the various similarities that 
exist between the two cell types, there are also significant differences (SHAH et 
ai, 1996), perhaps the most important of which being the contribution of each cell 
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type to cardiac function (BRUTSAERT, 2003). While VECs have an indirect 
effect on cardiac performance by controlling coronary blood flow supply to the 
myocardium (BRUTSAERT, 2003), EECs allow for direct cellular communication 
and signaling with cardiomyocytes due to their strategic anatomic location at the 
crossroads between the circulating blood and the underlying muscle 
(KURUVILLA and KARTHA, 2003) on the one hand, and their very close 
proximity to the subjacent cardiomyocytes on the other (BRUTSAERT, 2003). 
The importance of the crosstalk between the EE and myocardium appears 
early in fetal life due to the obligatory role that the EE plays in myocardial cell 
maturation and development (BRUTSAERT et al, 1998). Developing myocardial 
cells respond to signals from the endocardial layer to form the trabeculations that 
characterize the heart ventricles (MARCHIONNI, 1995; GASSMANN et al, 
1995; STANKUNAS et al, 2008). In mutant zebrafish embryos lacking the inner 
EE tubes, development of the outer myocardial layer remained dysmorphic and 
lacked trabeculation (LIAO et al, 1997). In addition, several studies have 
demonstrated that the crucial role of the EE goes even beyond cardiac 
development, for EECs are essential for the survival of postnatal cardiomyocytes 
and thus for the preservation of myocardial integrity (LEMMENS et al, 2006). 
Not only do EECs influence myocardial development and survival, but 
myocardial performance as well. The first suggestion of such a phenomenon came 
from the work of Brutsaert et al in 1988, where he reported that selective 
denudation of EECs in isolated cat cardiac papillary muscles resulted in a 
shortening of the duration of isometric twitch contractions with a concomitant 
- 7 -
decrease in peak twitch force (BRUTSAERT et al, 1988). Similar results were 
also reported later by the group of Fort et al. using the whole heart, but the 
magnitude of the effect was much smaller (FORT et al, 1993). Myocardial 
contractile performance is thought to depend primarily on the amount of transient 
[Ca "+] and the affinity of the contractile proteins in cardiomyocytes to the 
available calcium. The EE seems to modulate this affinity so that its damage 
decreases the Ca2+ responsiveness of myofilaments (WANG and MORGAN, 
1992). Two mechanisms have been proposed to explain the modulatory effect of 
the EE on myocardial performance: 1 - Upon stimulation, EECs secrete several 
factors that alter the contractile state of the subjacent myocytes (stimulus-
secretion-contraction coupling) (APPEN et al, 1993). 2 - The EE may act as a 
physicochemical barrier which controls the ionic constitution of the interstitial 
milieu surrounding the cardiomyocytes and consequently, it modulates their 
performance (EE as a blood heart barrier) (Figure 2) (BRUTSAERT et al, 1996; 
BRUTSAERT etal, 1998). 
1 - Stimulus-secretion-contraction coupling (factors release by EECs): release 
of factors from EECs occurs in response to various stimuli that result in an 
increase of LCa 2 + ] ; (KURUVILLA and KARTHA, 2003; JACQUES et al, 
2003b). This increase seems to occur in 2 phases: an initial transient phase due to 
the release of calcium from intracellular stores followed by a more sustained influx 
of calcium from the extracellular space (KURUVILLA and KARTHA, 2003). 
These factors, expressed and released by EECs, act in an autocrine or paracrine 
fashion to influence cardiac contractile performance and rhythmicity. They 
- 8 -
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include: nitric oxide (NO), endothelin-1 (ET-1), prostanoids, natrieuretic peptides, 
adenyl purines, reactive oxygen species (ROS), angiotensin II (Ang II), kinins and 
NPY (SHAH et al, 1996; BRUTSAERT, 2003; KURUVILLA and KARTHA, 
2003; JACQUES et al, 2003b). Many of these cardioactive mediators exert their 
effects on cardiac muscle through changes in myofilament properties rather than 
alterations of cytosolic Ca2+ transients (SHAH et al, 1994; SHAH et al, 1996). 
Moreover, EECs possess enzymatic activities such as angiotensin converting 
enzyme (ACE), kininase, constitutive nitric oxide synthase (eNOS) and endothelin 
converting enzyme (ECE activities); thus allowing this cellular layer to contribute 
to changes in the local levels of Ang II, bradykinin, NO and ET-1, respectively 
(SHAH et al, 1996; BRUTSAERT, 2003; KURUVILLA and KARTHA, 2003; 
ALONSO and RADOMSKI, 2003). 
2 - The endocardial endothelium as a blood heart barrier: the blood brain 
barrier (BBB) is the best-studied endothelial barrier possessing several unique 
features, the most important of which being its high transendothelial electrical 
resistance of ~ 1500-2000 Q.cirT as compared with other vascular endothelia (6-25 
Q.cm'), and the asymmetrical distribution of channels, pumps and transporters 
between the luminal and the abluminal surfaces of the brain capillary ECs 
(BRUTSAERT, 2003). By analogy to the BBB, the hypothesis that the EE may act 
as a blood heart barrier (BHB) was consequently considered (BRUTSAERT, 
1989). Its unique morphological as well as electrophysiological features support 
this hypothesis. EECs form a layer of closely apposed cells with deep and 
extensive interdigitations, abundant gap junctions and tight junctions located only 
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at the luminal side, suggesting unique permeability features (BRUTSAERT, 
2003). The Na+/K+ ATPase was also found to be typically confined to the luminal 
membrane of EECs from rats and rabbits (FRANSEN et ai, 2001). Moreover, the 
transendocardial electrical resistance was reported to be 50-80 Q.cm2 in near-
confluent porcine EE monolayers, a value 2 to 5 times higher than other endothelia 
(BRUTSAERT et ai, 1998). In light of all that was mentioned above, it could be 
suggested that the EE acts as a BHB, thus, maintaining ionic homeostasis of the 
interstitial milieu surrounding the subjacent excitable cardiomyocytes and 
contributing to the regulation of myocardial function (BRUTSAERT, 2003; 
KURUVILLA and KARTHA, 2003). 
Since the EE has been shown to be indispensable for cardiac maturation 
and growth, and since the crosstalk between the EE and the underlying 
myocardium is a very important modulator of cardiac performance and 
rhythmicity, it is not uncommon but rather logical that cardiac endothelial 
dysfunction could be involved in the development of heart disease (KURUVILLA 
and KARTHA, 2003). EE dysfunction can consist either of insufficient or of 
excessive performance of endothelial functions, and endocardial lesions have been 
widely reported in post mortem studies in various pathological conditions of the 
cardiovascular system (ANDRIES et ai, 1996). These diseases include ventricular 
aneurysms (HOCHMAN et ai, 1984), dilated cardiomyopathy (ROBERTS et ai, 
1987), hypereosinophilic endomyocardial fibrosis or Loffler's endocarditis 
(SPRY, 1987), hyperlipidemia (POPOV et ai, 1996) and many others. In most 
cases, EE lesions are accompanied by profound changes in the mechanical 
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performance of the myocardium which contributes to the etiology and progression 
of cardiac failure (BRUTSAERT, 2003). 
1.1.2 Right and left endocardial endothelial asymmetry 
A multitude of investigators have explored the issue of VEC heterogeneity, 
whether it is one relating to the appearance of endothelium from various vascular 
sites, or to the surface phenotype and protein expression of ECs from diverse 
tissues (CINES et ai, 1998). However, a few of them investigated the issue of 
heterogeneity, or more accurately left-right asymmetry, of the cardiac endothelium 
and more particularly, the endocardial endothelium. Among the reports on this 
subject and probably one of the most important is the fact that the architecture of 
the ventricular wall is much more elaborate in the right than in the left ventricle 
(BRUTSAERT, 2003). PGI2 release was demonstrated to be much higher from left 
EECs as compared to right EECs under conditions of increased transmural 
pressure (NOSAKA et ai, 1997). Moreover, Bmx tyrosine kinase gene was 
reported to be selectively expressed in left EECs but not in right EECs (EKMAN 
et ah, 1997). In contrast, cardiac natrieuretic peptide receptors exhibited a higher 
expression in right EECs as compared to left EECs (KIM et ai, 1999). Our group 
has recently provided more evidence regarding this concept of asymmetry between 
right (REECs) and left (LEECs) ventricular EECs, where it was demonstrated in 
2000 that ET-1 can induce a rise in free LCa2+]c and [Ca2+]n in REECs and LEECs 
of 20-week-old human fetal hearts. This effect seemed to be mediated mainly by 
the ETA receptor. However, the ETB receptor-mediated- ET-1 increase in Ca2+ 
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levels appeared to be limited to right EECs. In addition, it was reported that left 
EECs are more sensitive to ET-1 than right EECs, thus suggesting a difference 
between the two types of cells (JACQUES et ai, 2000a). We then showed in 2005 
that ET-1 and its receptors, ETA and ETB, are present at the level of REECs and 
LEECs isolated from 20-week-old human fetal hearts. However, ETB expression 
was higher in LEECs as compared to REECs, while ET-1 exhibited an opposite 
pattern of expression, higher in REECs as compared to LEECs (JACQUES et ai, 
2005). Moreover, our results on the presence of NPY and its receptors Y] and Y2 
in EECs show that NPY and the Yi receptor are present in REECs and LEECs 
isolated from 13, 17 and 20 week-old human fetal hearts, but with a different 
density in the 2 types of cells. Expression of Yi was shown to increase as a 
function of age in both REECs and LEECs, but at 13 and 17 weeks it was higher in 
right as compared to left EECs, an expression which was reversed at 20 weeks of 
age (SADER, 2002). Similarly, the Y2 receptor was found to be present at a higher 
density in 20-week-old LEECs when compared to REECs of the same age 
(PERREAULT, 2004). On the other hand, NPY expression in REECs increased as 
a function of age to attain a maximum at 20 weeks of age. However in LEECs, the 
highest expression of NPY was observed at 13 weeks. In addition, NPY induced a 
dose-dependent increase in both [Ca"+Jc and [Ca"+]n in REECs and LEECs, an 
effect which was mediated by the Yi receptor in LEECs, but by both Y] and Y2 
receptors in REECs. Finally, the increase in [Ca2+]; promoted the secretion of NPY 
into the extracellular medium by REECs, while the same increase induced NPY de 
novo synthesis in LEECs (SADER, 2002). Interestingly, it was even reported that 
there is a difference between arteries and veins in the ability of NPY to exert direct 
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constrictor effects or to potentiate the effect of other vasoconstrictor stimuli 
(MORRIS, 2004). It seems that NPY has greater contractile effects in veins 
(representing REECs) than in arteries (representing LEECs) (SMYTH et al., 
2000). 
All of the above-mentioned data indicate the existence of multiple 
differences between right and left EECs, a fact which suggests a difference in the 
contribution of right versus left EECs to the regulation of cardiomyocyte function 
in the human heart. In addition, these differences further endorse and extend the 
concept of the endocardial endothelium as a differential sensor device that 
regulates cardiac growth, contractile performance and rhythmicity (BRUTSAERT, 
2003). More information will hopefully be available in the near future on right-to-
left ventricular differences and the physiological implication of such a seemingly 
important asymmetry. 
1.1.3 The sensor and tuning roles of the endocardial endothelium 
Its unique position at the interface between the circulating blood on the one 
hand and the myocardium on the other, and at the entrance and exit of the 
pulmonary circulation indeed makes the EE very well-placed to play the role of 
the sensor device of the heart, if not the entire cardiovascular system 
(BRUTSAERT, 2003). This endothelium is exposed to all the circulating blood at 
least once every 2 minutes, and this value is increased by a factor of 4 or 5 during 
exercise (BRUTSAERT and ANDRIES, 1992; BRUTSAERT, 2003). On the other 
hand, the remaining cardiac endothelia, namely the coronary vascular endothelium 
and the endothelium of the myocardial capillaries, are exposed to around 5% of the 
circulating blood (BRUTSAERT et al, 1988). 
This sensor function of the EE is consistent with its morphological as well 
as electrochemical features. The numerous microvilli present on the luminal 
surface of EECs augment the contact surface area of the latter with the circulating 
blood and offer a high ratio of cavitary surface area to ventricular volume. 
Moreover, the abundance of gap junctions between EECs allows for rapid 
intercellular electrochemical coupling even after activation of only a single EEC 
(BRUTSAERT et al, 1998; BRUTSAERT, 2003). As part of its sensor role, the 
EE has also been shown to respond to many blood-borne factors. One might argue 
that this is the case with endothelial cells in other parts of the cardiovascular 
system as well. However, the EE is distinguished by the higher sensitivity of its 
responses to these circulating factors (BRUTSAERT, 2003) which include, among 
many others, Ang II (MEULEMANS et al, 1990) and ET-1 (LI et al, 1991). Also 
relevant to the concept of the EE as a sensor device is probably the asymmetry 
mentioned earlier between the right and left ventricular EE. Such differences 
between the REECs and LEECs suggest a differential sensor role of the right 
versus left EE, with the consequent effects on the underlying myocardium being 
right versus left ventricle-specific (BRUTSAERT, 2003). 
Being exposed to 100% of the circulation, the EE represents a very 
important source of endothelial enzymes and mediators and is a site in the 
endothelial system where the overall composition of the blood can be altered, 
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adjusted or normalized, hence the tuning role of the EE. Among the circulating 
mediators whose concentration is continuously adjusted by the EE are ET-1, Ang 
II, bradykinin and many others (BRUTSAERT, 2003). In the very important 
review about the endocardial endothelium by Brutsaert in 2003, it is proposed that 
in this sensor system composed of the right and left EE, it is the role of the right 
EE to sense any disturbances or variation in the composition of the incoming 
venous blood, and the left EE then adjusts this variation or 'normalizes' it to a 
certain set-point or target value (fine tuning). This ensures optimal delivery of the 
adjusted and stabilized blood-borne constituents to the peripheral organs 
(BRUTSAERT, 2003). 
These 2 interrelated functions of the EE as a sensor and tuning device in 
the cardiovascular system ultimately endorse the role of the EE as a very important 
modulator of cardiac contractile performance and rhythmicity (BRUTSAERT, 
2003). 
1.2 Neuropeptide Y 
NPY, a 36-amino acid peptide, was first isolated from porcine brain by 
Tatemoto et al. in 1982 (TATEMOTO et al, 1982). It belongs to a family of 
peptides that includes peptide YY (PYY) (70% homology) and pancreatic 
polypeptide (PP) (50% homology) (PEDRAZZINI et al., 2003) synthesized by the 
digestive tract (LARHAMMAR, 1996) and pancreatic endocrine cells (KIMMEL 
et al., 1975), respectively. NPY is conventionally known as a neurotransmitter that 
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is synthesized and released by neurons (PEDRAZZINI et al, 2003). In the 
periphery, sympathetic neurons represent the main source of NPY, where it is 
colocalized with norepinephrine (EKBLAD et al, 1984). NPY is also widely 
distributed in the central nervous system and represents one of the most abundant 
peptides in the mammalian heart and brain (EDVINSSON et al, 1987). NPY is 
thought to be involved in a multitude of physiological actions such as regulation of 
blood pressure, food intake, circadian rhythm, body temperature, memory 
processing as well as cardiovascular homeostasis (WAN and LAU, 1995; 
FRANCO-CERECEDA and LISKA, 1998). The NPY-family of peptides exerts its 
actions through a group of G-protein coupled receptors (GPCRs) (CERDA-
REVERTER and LARHAMMAR, 2000). These receptors include a post-synaptic 
Yi receptor, a presynaptic Y2 receptor, an NPY-preferring Y3 receptor, a PP or Y4 
receptor and a feeding receptor, namely Y5. All of the above-listed receptors, 
except for the Y3 receptor, have been cloned in several mammalian species 
(BLOMQVIST and HERZOG, 1997; BALASUBRAMANIAM, 1997; MICHEL 
et al, 1998). An additional receptor subtype was cloned recently and designated as 
y6. This receptor subtype, however, is functionally inactive in primates due to a 
frameshift mutation (MATSUMOTO et al, 1996). The prototype of Y, mediated 
actions in the periphery is vasoconstriction (LUNDBERG and TATEMOTO, 
1982), but in the CNS, it can also be involved in the stimulation of food intake 
(PEDRAZZINI et al, 2003). On the other hand, the presynaptic inhibition of 
norepinephrine release is the prototypical response mediated by NPY through its 
Y2 receptor (GRUNDEMAR, 1997). However, Y2 receptors may cause 
vasoconstriction in certain vascular beds and Yi receptors may exist 
- 18 -
prejunctional^ (FRANCO-CERECEDA and LISKA, 1998). The Y4 receptor, 
which is principally found in the gastrointestinal tract, is known for its capacity to 
inhibit gastric motility and secretion (QUIN et al, 1995; FELETOU et al, 1998; 
FELETOU et al, 1999), and the Y5 receptor is reported to stimulate food intake at 
the level of the hypothalamus (HU et al, 1996). 
The capacity of the different NPY receptors to bind the full-length peptides 
(NPY, PYY and PP), peptide fragments or peptide variants has been commonly 
used to differentiate these receptors (BECK-SICKINGER, 1997). For example, the 
full-length NPY can be cleaved by the membrane-bound protease, dipeptidyl 
peptidase IV (DPP IV), to generate NPY3.36 with reduced affinity for the Yi 
receptor but a retained capacity to bind to the Y2 and Y5 receptors (GRANDT et 
al, 1993). 
1.2.1 Presence of NPY and its receptors in the cardiovascular system 
More and more studies are unraveling the role of NPY in the 
cardiovascular system. This peptide, previously thought to be mainly a 
neurotransmitter synthesized and released by sympathetic neurons, appears to be 
quite abundant in the cardiovascular system (FRANCO-CERECEDA and LISKA, 
1998). One of the early studies to detect NPY receptors in vascular tissue was 
conducted by Leys et al. who reported the presence of NPY binding sites in small 
arteries of rabbit kidney (LEYS et al, 1987). Then Chang et al. in 1988 showed 
the presence of [123I]NPY binding sites in rabbit aorta (CHANG et al, 1988). In 
1991, Shigeri et al. also reported the presence of NPY binding sites in porcine 
aortic smooth muscle membrane fractions using I25I-Bolton-Hunter (125I-BH)NPY 
(SHIGERI et al, 1991). Another autoradiographical study conducted by 
Balasubramaniam et al. demonstrated NPY binding sites in cardiac tissue, and 
more particularly in rat ventricular membranes (BALASUBRAMANIAM et al, 
1990). In addition, Yi and Yo receptors were reported to be present in rat 
cardiomyocytes (MCDERMOTT et al, 1997) and in human myocardium and 
coronary arteries (UDDMAN et al, 2002). In 2003, the group of Rylander et al, 
using post-mortem human hearts and specific antibodies against the Y] and Y2 
receptors, revealed that both atrial and ventricular cardiomyocytes stained 
positively for the Yi and Y2 receptors, with the latter however being present at a 
higher density than the former. In this study as well, more coronary vessels stained 
positively for Y2 than Yi receptors, but those showing immunoreactivity for the Yi 
receptor were abundant in the subendocardium (JONSSON-RYLANDER et al, 
2003). The presence of the other NPY receptors in the cardiovascular system is 
studied to a much lower extent. The presence of the Y3 receptor in rat cardiac 
ventricular membranes was reported by the group of Balasubramaniam et al. 
(BALASUBRAMANIAM et al, 1990). Moreover, both the Y4 and y6 receptors 
were found to be present in the human heart (LUNDELL et al, 1995; 
MATSUMOTO et al, 1996). In addition, the Y4 receptor was reported to be 
present in rat aortic VSMCs but not VECs of the same aorta (BARRIOS et al, 
1999). As for the Y5 receptor, it was reported to be present in the heart as well as 
the blood vessels by a limited number of groups (BOROWSKY et al, 1998; 
PELLIEUX et al, 2000; PONS et al, 2003). In the study by Pellieux et al. and 
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using cardiac cells isolated from mice ventricles, Y5 receptor expression was 
readily detected in cardiomyocytes as well as non-myocyte cells (PELLIEUX et 
al, 2000). As for the peptide itself, NPY was found in high concentrations in the 
cardiac nervous system. NPY nerve fibers were seen in close contact with cardiac 
muscle fibers and were also found around the coronary vessels (GU et al, 1983). 
In another study by Onuoha et al on the presence of NPY in the hearts of several 
mammalian species including man, NPY displayed a higher concentration in the 
wall of the left atrium as compared to that of the right atrium in all the species 
studied except man. On the other hand, the density of NPY was about 40% higher 
in the wall of the right ventricle than that of the left ventricle in all of the species 
studied (ONUOHA et al, 1999). 
As can be observed from the above-mentioned data, a multitude of studies 
investigated the localization of NPY and its receptors in mammalian and human 
hearts. However, very few studies were conducted on the endothelium, be it 
vascular or endocardial endothelium. Recently, NPY was reported to be present in 
VECs of human umbilical vein (HUVECs) (GHERSI et al, 2001) and rabbit 
central ear artery (LOESCH, 2002). In 2003, Jacques et al demonstrated the 
presence of NPY and the Yi receptor in EECs of 20-week-old human fetal hearts. 
NPY and its Yi receptor appeared to have a similar distribution with a higher 
fluorescence labeling in the nucleus (particularly the nuclear envelope) as 
compared to the cytosol (JACQUES et al, 2003b). The same group also 
demonstrated that both REECs and LEECs isolated from human fetal hearts at 13, 
17 and 20 weeks of age possess NPY and its Yi receptor and that the expression of 
both changes as a function of age (SADER, 2002). Later in 2004, they also 
showed the presence of the Yo receptor in 20-week-old fetal right and left 
ventricular EECs. This receptor was present at the level of the cytosol and the 
nucleus of both cell types with a higher density at the nuclear level 
(PERREAULT, 2004). 
1.2.2 Biological effects of NPY at the level of the cardiovascular system 
Cardiovascular effects of NPY have been widely investigated since the 
discovery of NPY ~ 20 years ago. The two main NPY receptors thought to play a 
major role in the regulation of peripheral cardiovascular control are the Yi and Y2 
receptors (UDDMAN et al, 2002). NPY has been shown to be a potent 
vasoconstrictor with a slowly-developing and long lasting effect (PEDRAZZINI et 
al, 2003). The vasoconstrictor effects of NPY were demonstrated in several 
different isolated blood vessel preparations, including cat cerebral arteries 
(EDVINSSON et al, 1983), rabbit blood vessels (EDVINSSON et al, 1984), 
human coronary arteries (CLARKE et al., 1987; FRANCO-CERECEDA and 
LUNDBERG, 1987), human mesenteric veins, renal and skeletal muscle arteries 
(PERNOW et a!., 1987a; PERNOW et al, 1987b), rat vena cava (TSURUMAKI 
et al, 2003b) and guinea-pig vena cava (MALMSTROM and LUNDBERG, 1995) 
as well as rat intramyocardial arteries (PRIETO et al., 1998). Moreover, at doses 
that do not cause vasoconstriction, NPY has been shown to potentiate the action of 
other vasoactive substances (WAHLESTEDT et al., 1985; TSURUMAKI et al, 
2003a). In all of these studies examining the vasoconstrictor effect of NPY, it was 
always suggested that both the direct contractile effect and the potentiating actions 
of NPY are mediated by the Y, receptor (GRAD1N et al, 2003). In addition to 
NPY's potent vasoconstrictive effect on VSMCs, this peptide has been shown to 
stimulate DNA synthesis in human VSMCs (NILSSON and EDVINSSON, 2000) 
and proliferation in rat VSMCs (ZUKOWSKA-GROJEC et al, 1998a; PONS et 
al, 2003). In vitro, rat VSMCs responded bimodally to NPY by increased 
proliferation, and this effect was blocked by a Y1/Y5 receptor antagonist cocktail, 
thus implicating these 2 receptors in the mitogenic effect of NPY (KUO et al, 
2007). 
Documented actions of NPY on the heart are somewhat more divergent. It 
seems that the inotropic effect of NPY varies depending on the species and 
preparation used. Inotropy was not affected by NPY in human atrial strips 
(FRANCO-CERECEDA et al, 1987; MICHEL et al, 1989). However, negative 
inotropic effects were demonstrated in adult rat cardiomyocytes in a study by 
Millar et al. in 1991. On the other hand, a positive inotropic effect was obtained in 
the same study using adult guinea pig cardiomyocytes (MILLAR et al, 1991) and 
in another recent study where rat ventricular myocytes were utilized (HEREDIA et 
al, 2005). Debate is ongoing as to which NPY receptor mediates the above-
mentioned inotropic effect, but it has been suggested that the negative contraction 
effect of NPY is attributed to the Y2 receptor (MCDERMOTT et al, 1997), 
whereas that of positive contraction is attributed to the Y] receptor 
(MCDERMOTT et al, 1997; ALLEN et al, 2006). In addition to its controversial 
inotropic effect on the heart, NPY exerts long-term trophic effects that could be 
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involved in the hypertrophic response of the heart (ZENG et al, 2001). Evidence 
for the hypertrophic effects of NPY comes from studies utilizing rat 
cardiomyocytes in culture, where the authors reported an increase in protein mass 
and de novo protein synthesis (MILLAR et al, 1994; BELL et al, 2002). 
Experiments using selective NPY agonists and antagonists suggest that the 
hypertrophic effect of NPY in cardiac myocytes is mediated by the Y5 receptor 
(PELLIEUX et al, 2000; BELL et al, 2002). 
So far, the effects of NPY on the heart and vascular smooth muscle have 
been discussed thoroughly. However the growth-promoting actions of NPY seem 
to extend to the vascular endothelium as well, where NPY is reported to have an 
angiogenic effect (ZUKOWSKA-GROJEC et al, 1998b). In 1998, the group of 
Zukowska-Grojec et al reported that NPY is a potent angiogenic factor for human 
umbilical vein endothelial cells (HUVECs) and it exerts strong stimulatory effects 
on EC migration, proliferation and differentiation into capillary tubes in vitro. At 
that time, and using a limited number of receptor agonists and antagonists, the Y2 
and Y5 receptors were found to be mainly implicated in this angiogenic effect 
(ZUKOWSKA-GROJEC et al, 1998b). However, the full characterization of the 
receptor subtypes mediating migration, proliferation and capillary tube formation 
remained to be investigated. In 2006, it was demonstrated that NPY-induced EC 
migration was mimicked by agonists and fully blocked by antagonists for any 
specific NPY receptor (Yi or Y2 or Y5), while proliferation was blocked by any 2 
antagonists (Yi + Y2, Yi + Ys or Y2 + Y5) and capillary tube formation was 
blocked by the combined application of all 3 antagonists (Yi + Y2 + Y5). Thus, the 
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authors concluded that NPY-induced angiogenesis requires the participation of the 
Y), Y2 and Y5 receptor subtypes, with the Y5 receptor acting as an enhancer 
(MOVAFAGH et al, 2006). It is worth mentioning that in addition to its 
angiogenic effect on VECs, NPY was able to dose-dependently increase the 
permeability across rat aortic endothelial cell monolayers, an effect which seems 
to be mediated by the Y3 receptor (NAN et al, 2004). 
1.2.3 Signaling through NPY receptors 
NPY mediates its physiological actions through a group of 7-
transmembrane domain receptors that belong to the GPCR family (PEDRAZZINI 
et al, 2003). NPY receptor-mediated responses are almost always sensitive to 
inhibition by pertussis toxin (Ptx) suggesting predominant if not exclusive 
coupling to G-proteins of the Gi/o family (MICHEL et al, 1998). Therefore, NPY 
has been shown to inhibit adenylate cyclase and decrease the cAMP accumulation 
in a variety of cells and tissues (KASSIS et al, 1987; AAKERLUND et al, 1990). 
In addition, NPY receptor activation leads to activation of phospholipase C (PLC) 
which then stimulates the production of diacyl glycerol (DAG) and 
phosphatidylinositol triphosphate (IP3) (Figure 3) (SELBIE et al, 1995). 
Moreover, NPY is able to induce calcium mobilization and is linked to calcium-
signaling pathways (PEDRAZZINI et al, 2003). In fact, treatment of VSMCs with 
a specific PLC inhibitor blocked both the NPY-induced IP3 synthesis and calcium 
mobilization (SHIGERI et al, 1995). Not only does NPY mobilize calcium from 
the intracellular stores, but it also stimulates its influx across the plasma 
- 2 5 -
Figure 3. Intracellular signaling of NPY receptors. 
(XJ: a subunit of G; protein, (3y: (3y subunit of G; protein, GDP: 
guanosine diphosphate, GTP: guanosine triphosphate, AC: 
adenylate cyclase, cAMP: cyclic adenosine monophosphate, IP3: 
inositol triphosphate, DAG: diacylglycerol, PKC: protein kinase 
C, MAPK: mitogen-activated protein kinase. 
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membrane. Xiong et al. in 1993, reported that NPY was able to induce nifedipine-
sensitive calcium currents in SMCs from rat tail artery (XIONG et al, 1993). In 
addition, our group demonstrated in the year 2000 that human NPY was able to 
increase the frequency of cytoplasmic and nuclear Ca + transients in 
spontaneously-contracting chick ventricular myocytes, an effect that was blocked 
by nifedipine, and to induce a rise in both basal [Ca~+]c and [Ca"+]n levels in human 
aortic VSMCs (JACQUES et al., 2000b). Later in 2003, we showed, using human 
fetal EECs and EECs isolated from adult rat hearts, that NPY, dose-dependently, 
increased the free [Ca2+]c and [Ca2+]n in both cell types (JACQUES et al., 2003b). 
This NPY-induced increase of intracellular calcium, whether it is an influx across 
the plasma membrane or an intracellular calcium mobilization, has been associated 
with the Y, and Y2 receptor subtypes (JACQUES et al, 2000b; GROUZMANN et 
al, 2001; SADER, 2002; JACQUES et al., 2003b; HEREDIA et al, 2005). 
Whether other NPY receptors, such as the Y4, Y5 or y6 receptors, also stimulate 
calcium mobilization is not completely established yet (PEDRAZZINI et al., 
2003). 
Aside from its mobilization of calcium, NPY has been demonstrated to 
activate protein kinase C (PKC) which can lead to the activation of the mitogen-
activated-protein- kinase pathway (MAPK) (MANNON and RAYMOND, 1998; 
PELLIEUX et al, 2000). The Y, (MANNON and RAYMOND, 1998), Y2 (NIE 
and SELBIE, 1998; WONG et al, 1998) and Y5 receptors (PELLIEUX et al, 
2000) have all been coupled to PKC activation followed by activation of the 
MAPK pathway. In fact, Y5 receptor activation by NPY in mouse cardiomyocytes 
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led to the activation of PKC, and the down-regulation of the latter inhibited the 
resulting phosphorylation of ERK, p38 and JNK (PELLIEUX et al., 2000). These 
findings actually explain the growth-promoting actions of NPY (mitogenesis and 
angiogenesis) on VSMCs and VECs, respectively, as well as its hypertrophic 
properties in cardiomyocytes (MORRIS, 2004). 
1.3 Endothelin-1 
ET-1 is a 21-amino acid potent vasoconstrictive peptide purified from the 
supernatant of porcine aortic endothelial cells by Yanagisawa et al. in 1988 
(YANAGISAWA et al, 1988). It belongs to a family of isopeptides, including ET-
1, ET-2 and ET-3 that are encoded for by distinct genes but are all formed through 
a two-step processing pathway. ET-1, however, is the major isopeptide produced 
by human endothelial cells and is present in the blood in the greatest concentration 
as compared to ET-2 and ET-3 (GRAY and WEBB, 1996). The second and final 
step of ET-1 processing is catalyzed by a membrane-bound metalloproteinase 
called endothelin-converting enzyme (ECE) (OPGENORTH et al., 1992) which 
cleaves the ET-1 precursor, big ET-1, into the biologically active ET-1 (GRAY 
and WEBB, 1996). ET-1 mediates its actions via two G-protein coupled receptors, 
namely ETA and ETB (ALONSO and RADOMSKI, 2003). It acts through smooth 
muscle ETA and ETB2 receptors to produce vasoconstriction, cell growth and cell 
adhesion. Alternatively, it can bind to endothelial ETRI receptors to stimulate the 
release of NO and prostacyclins which results in vasodilation, prevent apoptosis 
and induce ET-1 clearance (ALONSO and RADOMSKI, 2003). ET-1 receptors 
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can be distinguished according to their ligand binding affinity to the 3 endothelin 
isoforms and the different specific agonists and antagonists (D'ORLEANS-JUSTE 
et al, 1996). The affinity of the ETA receptor to ET-1 and ET-2 is 100 times 
higher than that for ET-3, whereas the ETB receptor binds to the 3 isoforms with 
the same affinity (MASAKI, 1998; SCHNEIDER et al, 2007). ET-1 plays a role 
in both the physiology and pathology of the cardiovascular system whereby it 
participates in regulation of basal vascular tone (HAYNES and WEBB, 1994) and 
its altered expression could contribute to the development of diseases such as 
hypertension and atherosclerosis (HAYNES and WEBB, 1998). 
1.3.1 Presence of ET-1 and its receptors in the cardiovascular system 
As mentioned earlier, ET-1 was originally detected in VECs 
(YANAGISAWA et al, 1988), but since that discovery, there has been growing 
evidence that this peptide is also found in other cells of the cardiovascular system 
including VSMCs, cadiomyocytes and EECs as well. The association of ET-1 with 
the endothelial layer of human blood vessels of varying origin (TOKUNAGA et 
al, 1992; SAETRUM et al, 1994) as well as human VECs in culture (BKAILY et 
al, 2003a) is consistent with the idea that it can be released by ECs to act on the 
underlying smooth muscle layer. The ET-1 receptor, ETA, is principally found at 
the level of VSMCs (HORI et al, 1992; YANG et al, 1993), while the ETB 
receptor is predominantly expressed in ECs (OGAWA et al, 1991; MOLENAAR 
et al, 1993). However, our group has recently demonstrated the presence of the 
ETA receptor in human aortic endothelial cells (RIOPEL, 2006). In addition, we 
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showed that both ET-1 and the ETB receptor are also present in the cytosol and the 
nucleus of these cells as well as human VSMCs (BKAILY et al, 2003a). 
Besides their presence in vascular tissue, ET-1 and its receptors are also 
found in the heart. Mature ET-1 was detected in a number of human cardiac cells, 
including atrial and ventricular cardiomyocytes by the group of Wei et al. in 1994 
(WEI et al., 1994), and ET-1 immunoreactivity was localized in explanted human 
hearts by the group of Giaid et al. in 1995 (GIAID et al, 1995). 
Autoradiographical studies have also detected the presence of ET-1 receptors in 
both animal and human myocardium (DAVENPORT et al, 1989; MOODY et al, 
1990; MOLENAAR et al, 1993), and the receptor mRNA of ETA and ETB was 
found as well in atrial and ventricular myocardium (MOLENAAR et al, 1993). 
An analogous situation to that which exists in blood vessels, with ET-1 and its 
receptors being present in VECs and VSMCs, exists in the heart as well, where 
ET-1 and its receptors are not only localized in myocytes but in endocardial 
endothelial cells as well. In 1989, Power et al. reported the presence of ET-1 
receptors in EECs from laboratory animals (POWER et al, 1989) and Mebazaa et 
al. showed that cultured sheep EECs express mRNA of ET-1 (MEBAZAA et al, 
1993). In 1991, Hemsen at al. showed the localization of ET-like 
immunoreactivity in pig endocardium (HEMSEN and LUNDBERG, 1991) and 
Giaid et al. detected mature ET-1 in EECs (GIAID A. et al, 1991). Later in 2000, 
presence of mRNA of the ETA receptor was observed by Yanagisawa et al. at the 
level of murine endothelial endocardium (YANAGISAWA et al, 2000). In 2001, 
Opgaard et al. reported the presence of ET-1 in EECs, with a localization confined 
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to the cytoplasm of these cells. Furthermore, mRNA of ET-1 as well as its 
receptors ETA and ETB was detected in endocardial tissue (SAETRUM et al, 
2001). Very recently, the group of Jacques et al. demonstrated, using 
immunohistochemistry and 3D confocal microscopy, the presence of ET-1, ETA 
and ETB in EECs isolated from the right and left ventricles of human fetal hearts. 
ET-1 and the ETB receptor were found to be present at the level of the cytosol 
(including the plasma membrane) and more particularly at the level of the nucleus 
(including the nuclear envelope membranes) of both right (REECs) and left 
(LEECs) ventricular EECs. In contrast, the ETA receptor was found to be 
homogeneously distributed throughout the cytoplasm and nucleus of REECs and 
LEECs (JACQUES et al, 2005). 
1.3.2 Biological effects of ET-1 in the cardiovascular system 
The widespread expression and distribution of ET-1 and its receptors, ETA 
and ETB, in cardiovascular tissues suggests that this system plays a very important 
role in cardiovascular control (GRAY and WEBB, 1996). Abundant evidence in 
the literature indicates that i.v. administration of ET-1 results in a biphasic 
response, with an initial transient hypotensive effect followed by a prolonged 
vasoconstrictor effect which can last for more than an hour. This pattern has been 
observed in almost all animals including humans (BRUNNER et al, 2006). It is 
now well-established that the initial hypotensive phase requires an intact 
endothelium and is mediated by the endothelial ETB receptors with a resulting 
generation of vasodilators, such as NO (GRANSTAM et al, 1993; FILEP et al, 
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1993; D'ORLEANS-JUSTE et al, 2002), and the second vasoconstrictor phase is 
mediated by the smooth muscle ETA receptor (BRUNNER et al, 2006). Initially, 
it was thought that the ET-1 -induced vasoconstriction is mediated solely by the 
ETA receptor, however further evidence suggested the implication, as well, of the 
ETB receptors in this vasoconstrictive effect (HAYNES et al, 1995). This 
implication however is variable and seems to depend on the species, vessel size 
and vessel type under question (DAVENPORT and MAGUIRE, 1994). In addition 
to its vasoconstrictive effect, ET-1 seems to be a potent mitogenic and 
proliferative factor for VSMCs. Application of ET-1 to cultures of rat VSMCs 
resulted in a rapid increase in the c-fos and c-myc mRNA levels and stimulated the 
DNA synthesis of in a dose-dependent manner (KOMURO et al, 1988; BOBIK et 
al, 1990). These growth-promoting effects of ET-1 on VSMCs seem to be 
mediated by the ETA receptor (OHLSTEIN et al, 1992) and they suggest the 
implication of ET-1 in hyperplasia and atherosclerosis (BRUNNER et al, 2006). 
The mitogenic effect of ET-1 on VECs was investigated as well by various 
research groups. Cell proliferation (measured as DNA synthesis and as total cell 
number) and migration of endothelial cells from bovine adrenal capillaries 
(BACE) and from the human umbilical vein (HUVECs) were significantly 
increased by ET-1. Both effects seemed to be mediated by the ETB receptor 
(MORBIDELLI et al, 1995; ZICHE et al, 1995). By favoring endothelial cell 
growth and migration, it was suggested that ET-1 plays an important role as an 
endothelial cell angiogenic factor and can thus contribute to neovascularization in 
vivo, especially since it was able to enhance HUVEC differentiation into cord 
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vascular-like structures on Matrigel (SALANT et ah, 2000). This ET-1-induced 
endothelial cell migration seems to be due to the stimulation of NO production by 
ET-1, mediated through the ETB receptor (NOIRI et ah, 1997; GOLIGORSKY et 
ah, 1999). 
In addition to its biological effects on the vascular tissue, ET-1 seems to 
have important myocardial effects, for it can modulate the contractile and the 
growth properties of cardiomyocytes (BRUNNER et ah, 2006). ET-1 elicits a 
positive inotropic effect in cardiac muscle isolated from most mammalian species 
including human (TAKANASHI and ENDOH, 1991; MEYER et ah, 1996) and 
increases cell shortening in isolated cardiomyocytes (KELSO et ah, 2000). 
However, besides dicing positive inotropic effects, ET-1 can depress contractility 
in certain experimental conditions and preparations, for a negative inotropic 
response was demonstrated in mouse ventricle and in rabbit atria after stimulation 
with ET-1 (ZHU et ah, 1997; IZUMI et ah, 2000). Debate is still ongoing as to 
which receptor mediates the inotropic effects of ET-1. The positive inotropic 
response seems to be generally attributed to the ETA receptor (MEYER et ah, 
1996; KELSO et ah, 2000). However, some groups demonstrated an exclusive role 
for the ETB receptor in mediating the positive inotropic effect (BEYER et ah, 
1996). As to the negative inotropic effect of ET-1, it is still unclear which 
receptor(s) is implicated in this effect but a few groups reported an involvement of 
the ETB receptor (LEITE-MOREIRA and BRAS-SILVA, 2004). Moreover, ET-1 
is reported to have a hypertrophic effect on the heart, for it stimulated a significant 
increase in the total mass of cellular protein and the cell surface area of cardiac 
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myocytes (ITO et al, 1991; SUGDEN et al, 1993). Most authors attributed the 
ET-1 induced myocardial growth to the ETA receptor (SUGDEN et al, 1993; 
BRUNNER et al, 2006), some to the ETB receptor (CULLEN et al, 2001; LEE et 
al, 2004) and yet others to both receptors (MULLAN et al, 1997). 
Aside from all that has been mentioned above, ET-1 seems to have a role 
as well in the survival of VSMCs, VECs and cardiomyocytes for it has been 
reported to attenuate their apoptosis. This antiapoptotic effect of ET-1 seems to be 
mediated by the ETA receptor in VSMCs and cardiomyocytes, but via the ETB 
receptor in endothelial cells (SHICHIRI et al, 1997; SHICHIRI et al, 2000; 
OGATAS al, 2003). 
1.3.3 Signaling through ET-1 receptors 
ET-1 binds with very high affinity to its heptahelical transmembrane 
receptors, ETA and ETB, which belong to the large family of GPCRs and which 
seem to employ similar signaling cascades (SCHIFFRIN and TOUYZ, 1998). 
There is much evidence in the literature reporting that ET-1 receptors utilize both 
Ptx sensitive and insensitive G proteins (HILAL-DANDAN et al, 1992; HILAL-
DANDAN et al, 1997). This suggests that ET-1 activation of its receptors can 
elicit diverse pathways of signal transduction by activating multiple G proteins 
which, in turn, activate a single or multiple effectors (SCHIFFRIN and TOUYZ, 
1998). Upon binding of ET-1 to its receptors on the cell membrane, the signaling 
pathways that are activated can be divided into 2 types: those mediating the short-
term and those mediating the long-term cellular effects of ET-1. Short-term 
cellular effects include excitation-contraction and/or secretion coupling (BKAILY 
et al, 1997), whereas the long-term effects include cell growth, hypertrophy, 
proliferation, migration and cell survival (SCHIFFRIN and TOUYZ, 1998; 
BOUALLEGUE et al, 2007). 
Signaling pathways mediating the short-term effects of ET-1 include the 
stimulation of phosphoinositide hydrolysis (HILAL-DANDAN et al, 1992) by 
activation of membrane-bound PLC, which hydrolyzes PIPi into the second 
messengers IP3 and DAG. IP3 mobilizes calcium from intracellular stores, whereas 
DAG activates PKC (Figure 4) (GRIENDLING et al, 1989; FLUCKIGER et al, 
1992; RICORT, 2005). The activation of PKC by ET-1 has been demonstrated in 
VSMCs (MCNAIR et al., 2004) and cardiomyocytes (CHILOECHES et al, 1999) 
where PKC has been suggested to participate in the ET-1 stimulated contraction by 
promoting intracellular alkalinization through activation of the Na+/H+ exchanger 
and thus increasing the sensitivity of contractile myofilaments to calcium 
(LONCHAMPT et al, 1991; WOO and LEE, 1999; BRUNNER et al, 2006). 
PKC can also phosphorylate calcium channels, such as the L-type calcium 
channel, and thus result in the influx of calcium across the plasma membrane (HE 
et al, 2000). In fact, our group demonstrated in 1995 that ET-1 can stimulate both 
T- and L-type Ca"+ currents in human and chick ventricular myocytes, an effect 
which was blocked by the ETA receptor antagonist, BQ123 (BKAILY et al, 
1995). Then in 2003, we reported that ET-1 can induce a rise in the cytosolic and 
nuclear calcium levels in human aortic VSMCs (BKAILY et al, 2003a). This 
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ET-1-induced rise in calcium is seen in endothelial cells as well. Kawaguchi et al. 
in 1991, using bovine pulmonary artery endothelial cells, reported that ET-1 
induced an increase in [Ca +]j, an effect which was mediated by the PLC-IP3 
pathway (KAWAGUCHI et al., 1991). Moreover, our group showed in 2000 that 
ET-1 increased, dose-dependently, the [Ca'+]c and [Ca2+]n in EECs, and that this 
effect seems to be mediated mainly by the ETA receptor (JACQUES et al, 2000a). 
This intracellular rise of calcium can either stimulate the contractile machinery or 
promote secretion depending on the cell type in question (contraction in myocytes 
and VSMCs and secretion in ECs) (DE NUCCI et al., 1988; MILLER et al, 1993; 
KAN AIDE, 1996). 
In addition to all what has been mentioned about the short-term signaling 
of ET-1, it was reported that in some cells ETA and ETB receptors may couple to 
adenylate cyclase and guanylate cyclase, but the data about that seems to be 
inconsistent (for more details refer to (SCHIFFRIN and TOUYZ, 1998)). 
Moreover, ETA and ETB receptor activation has been shown to stimulate PLA2 
activity leading to the production of mediators such as prostaglandins, 
thromboxanes and leukotrienes (VIGNE and FRELIN, 1994; KRUGER et al, 
1995). 
As mentioned earlier, ET-1 promotes several long-term biological effects 
including the growth and proliferation of various cell types such as VSMCs, VECs 
and cardiomyocytes. A key signaling pathway needed for this mitogenic effect of 
ET-1 is the MAPK cascade (Figure 5). The activation of ERK1/2 by ET-1 has 
been demonstrated by several research groups in many cell types including 
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cardiomyocytes (YUE et al, 2000) and VSMCs (DAOU and SRIVASTAVA, 
2004). Moreover, the group of Clerk et al. showed that ET-1 stimulates the 
translocation of PKC to the cell membrane of ventricular cardiomyocytes, and this 
is followed by the phosphorylation and thus the activation of p42/p44 (CLERK et 
al, 1994). Such activation of MAPK leads to the expression of transcription 
factors required for cellular proliferation such as c-fos and c-myc (KOMURO et 
al, 1988; DOUGLAS and OHLSTEIN, 1997) and is implicated in the 
antiapoptotic effect of ET-1 (WU-WONG et al, 2000). Among the long-term 
effects of ET-1 is intercellular matrix deposition (collagen deposition) in both the 
vasculature and the heart, which suggests the implication of this peptide in 
vascular and heart remodeling (SCHIFFRIN and TOUYZ, 1998). This was 
demonstrated by the group of Kuruvilla et al. who showed that ET-1 secreted by 
endocardial endothelium isolated from porcine heart stimulated the proliferation of 
fibroblasts and the synthesis of collagen via a signaling pathway involving PKC 
and MAP kinases. This effect was mediated by the ETA receptor (KURUVILLA et 
al, 2007). 
1.3.4 Secretion of ET-1 by endothelial cells 
ET-1 was originally identified in the culture supernatant of porcine aortic 
endothelial cells (YANAGISAWA et al, 1988) suggesting that this peptide can be 
released by these cells. Since then, many reports have provided evidence showing 
that ET-1 can be released by endothelial cells, be it VECs or EECs. Mebazaa et al. 
reported in 1993 that cultured sheep ventricular EECs tonically release 
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subnanomolar concentrations of ET-1 (MEBAZAA et ai, 1993). In addition, 
release of ET-1 has been reported from cultured porcine EECs (SINEY and 
LEWIS, 1994), rat cardiac microvascular ECs in coculture with myocytes 
(NISHIDA et ai, 1993) and from cultured bovine carotid artery ECs (EMORI et 
ai, 1989). ET-1 is thought to be released tonically from these endothelial cells to 
maintain basal vascular tone (HAYNES and WEBB, 1994), and its release is 
suggested to be predominantly in an abluminal direction towards the underlying 
smooth muscle layer (WAGNER et ai, 1992). In addition to its tonic release by 
endothelial cells, many extracellular factors (both physical and chemical) can 
modulate the generation and release of ET-1 through a series of intracellular 
mediators (GRAY and WEBB, 1996). Some of these factors (e.g. hormones, 
thrombin, low shear stress...) stimulate and others (Prostacyclin, NO, high shear 
stress...) inhibit the release of ET-1. Many of the stimulatory factors act 
predominantly through inducing a rise in the cytosolic free calcium concentration 
(DATTA and EWENSTEIN, 2001) and activation of the PLC/PKC pathway, 
whereas the inhibitory factors mediate their actions via cGMP (GRAY and 
WEBB, 1996; HAYNES and WEBB, 1998; BRUNNER et ai, 2006). It was 
previously presumed that secretion of ET-1 from endothelial cells is regulated 
predominantly at the level of transcription and translation of the mRNA and thus 
necessitates de novo protein synthesis. However, further evidence from several 
research groups could not totally endorse this concept (TASAKA and 
KITAZUMI, 1994). For example, calphostin C, a specific PKC inhibitor, was 
ineffective at completely inhibiting the thrombin-induced secretion of ET-1 from 
endothelial cells, despite its ability to completely abolish the thrombin-induced 
- 4 3 -
expression of ET-1 mRNA (KITAZUMI and TASAKA, 1992; KITAZUMI and 
TASAKA, 1993). In addition, when healthy volunteers were subjected to a cold 
pressor test, there was a rise in the venous ET-1 concentration detected within 2 
minutes, a time period which is insufficient for de novo synthesis of the peptide 
(FYHRQUIST et al, 1990). This suggested therefore that the secretion of ET-1 
could be regulated at various stages after transcription and that the peptide can be 
released, upon demand, from intracellular stores (TASAKA and KITAZUMI, 
1994; RUSSELL and DAVENPORT, 1999). Two distinct exocytic pathways were 
thus proposed for the release of ET-1 from endothelial cells: a constitutive and a 
regulated pathway (Figure 6) (RUSSELL et al, 1998; DATTA and EWENSTEIN, 
2001). Small secretory vesicles continuously budding from the trans- Golgi 
network and directed towards the cell membrane are responsible for the tonic, 
constitutive secretion of ET-1 (RUSSELL and DAVENPORT, 1999). In fact, ET-
1 -like immunoreactivity was detected in bovine aortic and human coronary artery 
endothelial cell secretory vesicles (HARRISON et al, 1995; RUSSELL et al, 
1998). On the other hand, Weibel-Plade bodies (WEIBEL and PALADE, 1964), 
which are endothelial cell specific storage granules, participate in the release of 
ET-1 following an appropriate stimulus (DATTA and EWENSTEIN, 2001). Using 
immunoelectron microscopy, the groups of Hamasaki et al and Russell et al 
demonstrated the localization of ET-1 in Weibel-Palade bodies in human 
endothelial cells (HAMASAKI etal, 1995; RUSSELL etal, 1998). 
Several studies have tried to examine the polarity of protein secretion from 
endothelial cells in both the constitutive and the regulated pathway, but there is 
- 44 -

Ex
te
rn
al
 
St
im
ul
us
 
IP
 
^
M
«?
?7
^S
tv
 
*
 
*
 
'm
 
m
 
•
 
•
™
Q
L 
H
np
tfp
 
E
iH
U
I 
"
w
"
'*
*
*
*
!;;
 
m
 
still some controversy regarding this issue. The constitutive release of von 
Willebrand factor (vWF), a glycoprotein that also has a dual secretory pathway 
and that colocalizes with ET-1 in Weibel-Palade bodies, was reported to be 
nonpolarized (SPORN et ai, 1989). However, around 80% of the constitutive 
secretion of ET-1 from endothelial cells was reported to be towards the abluminal 
surface (WAGNER et al, 1992). As for the regulated secretory pathway, polarized 
secretion of vWF towards both the basolateral and the luminal membranes of 
endothelial cells, as well as non-polarized secretion were all reported for this 
glycoprotein (SPORN et al, 1989; BUUL-WORTELBOER et al, 1989). On the 
other hand, in a study conducted by Ferri et al. in 1999, 75% of the stimulated 
secretion of ET-1 was shown to be to the basolateral side of HUVECs (FERRI et 
al., 1999). As for endocardial endothelial cells, it is unclear if the release of ET-1 
from these occurs in the abluminal direction as well (i.e. towards the myocardium) 
but this was suggested by the groups of Mebazaa et al. and Tonnessen et al., who 
proposed that endothelin might influence cardiac contraction by direct diffusion to 
the subendocardial myocardium (MEBAZAA et al., 1993; TONNESSEN et al., 
1993). 
1.4 Cross-talk between ET-1 and other cardioactive mediators 
Endothelial cells perform their functions through the expression and 
release of various cardioactive factors such as ET-1, Ang-II, NO and prostanoids 
(SHAH et ai, 1996; CINES et ai, 1998). Both vascular endothelial as well as 
endocardial endothelial cells have been reported to release these factors 
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(BRUTSAERT, 2003; KURUVILLA and KARTHA, 2003). Over the last years, 
complex interactions have been reported to exist between ET-1 and the other 
regulators of cardiovascular function, in particular NO and Ang II (BRUNNER et 
al, 2006). Stated in simple words, it has been shown that ET-1 acts on endothelial 
ETB receptors to increase the release of NO. In contrast, NO produced basally and 
following agonist stimulation inhibits the release of ET-1 from endothelial cells 
(WARNER, 1999; ALONSO and RADOMSKI, 2003). Evidence for the former 
effect comes from a study by Warner et al., who demonstrated using bovine 
endothelial cells that ET-1 is able to stimulate NO release (WARNER et al, 
1992), whereas evidence for the latter effect is provided by the group of Mitsutomi 
et al. who showed that NO inhibited the production of ET-1 in porcine aortic 
endothelial cells (MITSUTOMI et al, 1999). Although, it is commonly accepted 
that ET-1 can induce the release of NO, the signaling pathways underlying this 
effect have been poorly characterized. In a review by Alonso et al., he reported 
that endothelial ETB receptor stimulation results in PLC activation, followed by an 
increase in the intracellular calcium level which leads to upregulation of 
endothelial cell nitric oxide synthase (eNOS). He also stated that a PKC-dependent 
pathway could be involved (ALONSO and RADOMSKI, 2003). On the other 
hand, the group of Liu et al. demonstrated, using sinusoidal endothelial cells, that 
ET-1 binding to ETB receptors on these cells led to increased protein kinase B/Akt 
phosphorylation, which in turn led to eNOS phosphorylation and NO synthesis. 
Furthermore, they showed that this ET-1 induced effect was sensitive to treatment 
with Ptx (i.e. G;/0-mediated) (LIU et al., 2003). As for the modulation of ET-1 
secretion by NO or NO donors, both cGMP-dependent and independent 
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mechanisms have been suggested. In a study by Ohkita et al. in 2003, the authors 
suggested that a cGMP-dependent pathway involving the inhibition of nuclear 
factor-KB activation is implicated in the reduced secretion of ET-1 elicited by NO 
in vascular endothelial cells (OHKITA et al, 2003). In contrast, Brunner et al, 
using porcine aortic endothelial cells, demonstrated that NO is able to decrease the 
secretion of ET-1 in a cGMP-independent manner (BRUNNER et al, 1995). 
Evidence for interactions between the endothelin and the angiotensin 
system has also become plentiful. It has become clear that the two systems, in 
addition to acting independently, can act synergistically. In 1989, Emori et al. 
showed that Angll could stimulate release of ET-1 in porcine aortic ECs (EMORI 
et al, 1989). In 1991, Kawaguchi et al. reported that ET-1 can induce ACE 
activity in cultured pulmonary artery ECs (KAWAGUCHI et al, 1991). Then in 
1992, Imai et al. demonstrated, using cultured bovine carotid artery ECs (BCAE) 
that Angll induced ET-1 mRNA expression (IMAI et al, 1992). In accordance 
with these results, Chua et al. provided evidence that Angll can promote ET-1 
mRNA production in ECs derived from a variety of sources including heart, aorta 
and resistance vessels of mesenteric arteries (CHUA et al, 1993). Moreover, Ferri 
et al, in 1999, demonstrated that Angll is a powerful stimulator of ET-1 de novo 
synthesis as well as release from cultured HUVECs, an effect that appeared to be 
mediated by the AT] receptor (FERRI et al, 1999). In contrast, in a study 
conducted by McEwan et al, investigating the influence of chronic Angll infusion 
on the expression of ET-1, ETB and ETA mRNA in rat hearts, it was demonstrated 
that only Angll administered with losartan, an AT] receptor antagonist, was able to 
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increase mRNA of ET-1 and the ETB receptor (MCEWAN et al, 2000). It is 
suggested that the Ang II induction of ET-1 mRNA and release is mediated via a 
mechanism that involves PKC (CHUA et al, 1993; ORIJI, 1999). Responsiveness 
to PKC is mediated by binding of the activated Jun and Fos proteins to the 
Activator Protein-1 (AP-1) responsive element on the ET-1 promoter (CURRAN 
and FRANZA, JR., 1988; LEE et al, 1991). In the heart, it has been reported that 
the positive inotropic effect of Ang II, depends to a large extent, on ETA receptor 
activation (CASTRO-CHAVES et al, 2006). Moreover, Ang IT induced ET-1 
gene expression and release in cardiomyocytes, an effect which seems to be 
essential for mediating the cardiac hypertrophic effects of Ang II (IMAI et al, 
1992; ITO et al, 1993; ROSSI etal. 1999). 
In addition to the intimate crosstalk that exists between ET-1, Ang II and 
NO, ET-1 has interactions with other cardioactive mediators. ET-1 has been 
reported to increase the production of prostacyclin (PGI2) by cultured endothelial 
cells (SUZUKI et al, 1991), whereas both PGI2 and prostaglandin E2 (PGE2) 
caused a reduction in ET-1 de novo synthesis and secretion (PRINS et al, 1994). 
ET-1 has a close relationship as well with the natriuretic peptides. Evidence in the 
literature shows that ET-1 is a potent stimulator of natriuretic peptide secretion 
(DIETZ, 2005). Cardiac natriuretic peptides, on the other hand, were found to 
inhibit ET-1 production. In addition, ET-1 was reported to antagonize the 
apoptosis of ECs and myocytes induced by these peptides through a cGMP-
dependent mechanism (for more details on the crosstalk between ET-1 and the 
natriuretic peptides refer to (HAN and HASIN, 2003). Interestingly, ET-1 seems to 
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influence its own generation and release as well. In a study by Evans et al. in 
2003, using human aortic endothelial cells, the authors showed that treatment of 
the aforementioned cells with ET-1 increased the number of cells secreting ET-1 
itself. This effect of ET-1 on its own release seemed to be mediated by the ETB 
receptor (EVANS et al, 2003). In another recent study by Peled et al, it was 
demonstrated that ETB, but not ETA, receptor blockade increased preproET-1 
transcription both in vivo and in vitro, with bovine aortic endothelial cells being 
used in the latter case (PELED et al, 2006). Similarly, Sanchez et al. found an 
increase in the ET-1 mRNA levels following ETB receptor blockade (SANCHEZ 
e? a/., 2002). 
In contrast to the abundant evidence in the literature about the crosstalk 
that exists between ET-1 and other cardioactive mediators, few reports are 
available on interactions between NPY and other cardiovascular mediators, 
particularly between NPY and ET-1. In a study in 1998 by Fabi et al., the authors 
reported using segments of the human saphenous vein that the NPY-induced 
potentiation of the noradrenaline vasoconstrictor effect is mediated through NPY's 
action on endothelial cells to stimulate the release of the cyclooxygenase 
metabolite, thromboxane A2 (FABI et al, 1998). In another study conducted on 
porcine aortic smooth muscle cells, the authors showed that even though NPY had 
no effect on the IP3 level in these cells, it was able to potentiate the effect of Ang 
II on IP3 production (SHIGERI et al., 1995). Moreover, in a recent study by Zeng 
et al. in 2002, there was a dose-dependent decrease in the plasma concentration of 
NPY in rats that were treated with the angiotensin-converting enzyme (ACE) 
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inhibitor, peridopril. This suggested that a lowered plasma NPY concentration 
might play a role in the anti-hypertensive mechanisms of the ACE inhibitors 
(ZENG et ai, 2002). As for interactions existing between NPY and ET-1, it has 
been suggested that ET-1 attenuates sympathetic neurotransmission (HOANG et 
ai, 2002). Since NPY is one of the most abundant neurotransmitters released by 
sympathetic neurons innervating vascular smooth and cardiac muscle, Hoang et ai 
in the year 2002, investigated the role of ET-1 on the evoked release of NPY using 
a perfused rat mesenteric arterial bed. He showed that ET-1 was able to attenuate 
NPY release, upon high frequency nerve stimulation. This effect was significantly 
blocked by the ETA/ETB receptor antagonist, PD142893, and by the selective ETB 
antagonist RES-701-1 but not by the ETA receptor antagonist BQ123. In addition, 
the ETB agonist, STX6C, was able to mimic the ET-1 effect, thus suggesting that 
ET-1-induced inhibition of NPY is mediated by the ETB receptor (HOANG et ah, 
2002). In contrast to these results and in a study conducted by Gardner et al. in 
2005, the author used NGF-differentiated rat pheochromocytoma (PC 12) cells to 
examine the effect of ET-1 on sympathetic release of NPY, ATP and dopamine. 
His results showed that ET-1 inhibited release of ATP, but not dopamine or NPY 
(GARDNER era/., 2005). 
1.5 Summary of the literature and research hypothesis 
The endocardial endothelium is a monolayer of closely-apposed endothelial 
cells that lines the heart cavities. This cellular layer seems to play a crucial role 
in myocardial maturation, performance and rhythmicity. The endocardial 
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endothelial modulation of cardiac function is mediated mainly through the 
release of different factors, such as ET-1, Ang II, NO and natriuretic peptides. 
Our group has recently demonstrated the presence of ET-1 and its receptors, ETA 
and ETB as well as NPY and its receptors Yi and Y2 in both right and left human 
ventricular EECs. Moreover, we showed that both ET-1 and NPY can induce a 
rise in the [Ca'+Jc and fCa +Jn in these cells and that NPY can be released from 
these cells after a stimulated increase in the [Ca +]; level. An asymmetry was 
observed between the right and left ventricular EECs regarding each of the 
results listed above. In addition to the results obtained by our group, the 
literature provides evidence about the important roles that ET-1 and NPY play in 
cardiovascular control, especially that both can modulate cardiac contractility 
and stimulate myocyte hypertrophy, as well as induce proliferation and 
angiogenesis of VSMCs and endothelial cells, respectively. Furthermore, there 
are abundant reports in the literature about the existence of complex interactions 
and intimate crosstalk between ET-1 and the other cardioactive mediators, 
particularly between ET-1, Ang II and NO. Taken together, all of the above-
listed data led us to formulate the hypothesis that a dialogue can equally exist 
between the systems of NPY and ET-1 at the level of human right and left 
ventricular endocardial endothelial cells. In order to test this hypothesis, we 
plan to answer the following questions: 
1. Does NPY induce the secretion of ET-1 at the level of REECs? If yes, 
a. Does this NPY-induced secretion of ET-1 occur at the level of LEECs as 
well? If yes, 
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b. Are there any differences between REECs and LEECs in the NPY-
inducedET-1 secretion? 
2. Is this secretion due to activation of the Y] and/or the Y2 receptor(s)? 
3. Is the Y5 receptor also implicated in the NPY-induced secretion of ET-1 at 
the level of REECs and/or LEECs? 
4. Does the secreted ET-1 by NPY contribute to its own release via activation of 
its ETA and/or ETB receptor(s)? 
In order to answer the above-listed questions, we used cultured EECs isolated 
from the right and left ventricles of 20-week-old human fetal hearts throughout 
this study. In addition, we used the techniques of indirect immunofluorescence 
accompanied by 3-dimensional confocal microscopy, as well as the technique of 
ELISA to examine ET-1 secretion (if any) elicited by NPY at the level of EECs. 
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II. MATERIALS & METHODS 
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2.1 Isolation and culture of endocardial endothelial cells from 20-
week-old human fetal hearts 
Endocardial endothelial cells (EECs) were isolated from the right and left 
ventricles (REECs and LEECs, respectively) of 20-week-old human fetal hearts as 
described previously by our group (BKAILY et al, 1997; JACQUES et ah, 
2000a). The method used fulfills the recommendations of the ethical committee 
regarding the use of human material. 
Human fetal hearts were isolated under asceptical conditions. They were 
immediately immersed in a beaker containing a sterile solution of S-MEM 
(Suspension of Minimal Essential Medium) having the following composition: 
NaCl (120 mM), KC1 (5 raM), MgS04 (0.8 mM), NaH2P04 (10 mM) (Gibco BRL; 
Burlington, Ont.) and supplemented with Penicillin-G-Potassium (Ayerst; 
Montreal, QC). The heart ventricles were then opened and cleaned from blood 
using sterile medium Ml99 (Gibco BRL, Burlington, Ont.) which contains 
Penicillin and Streptomycin (Gibco BRL; Burlington, Ont.) and has the following 
composition: Earle's Salts, L-glutamine and 2.2 g/L sodium bicarbonate. In order 
to isolate the REECs and LEECs, the opened ventricles were placed in a culture 
Petri dish, with their luminal surface facing upwards, and were exposed to Ml99 
solution containing 0.05% trypsin for 5 minutes (Whittaker; Walkerville, MD). 
Following the trypsin treatment, the endocardial endothelium of both ventricles 
was gently scraped using a scalpel blade. The scraped cellular layer was washed 
and suspended in medium Ml99 (Gibco BRL; Burlington, Ont.) supplemented 
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with 10% FBS (fetal bovine serum) (Gibco BRL, Burlington, Ont.). After a 10-
minute centrifugation period at 1000 rpm (revolutions per minute), the supernatant 
was discarded and the cellular pellet resuspended in medium Ml99 supplemented 
with 10% FBS. Finally, cells were spread onto Petri dishes and placed in an 
incubator maintained at 37°C and 5% CO2. The cell culture was done on 25 mm 
coverslips laid in 35 mm Petri dishes if cells were to be used for 
immunofluorescent studies followed by 3-dimensional (3-D) confocal microscopic 
examination, or 100 mm Petri dishes if cells were to be used for ELISA (enzyme-
linked immunosorbent assay). For producing primary cell cultures, the suspended 
REECs and LEECs are spread in culture flasks (GibcoBRL, Burlington, Ont.) and 
incubated under the conditions mentioned above. Upon confluence, cells are 
trypsinized and reseeded in medium Ml99 supplemented with 10% FBS 
(BKAILY etai, 1997). 
A test for the quality and purity of REECs and LEECs is routinely done in 
our lab using an FITC-conjugated fluorescent probe, namely Lectin Ulex 
Europeans Agglutinin, (6pg/ml; Sigma, St-Louis, MO). This probe binds to a-
linked fucose residues known to be present on the surface of endothelial cells 
(BKAILY et ai, 1997; JACQUES et al, 2000a). A second test, also routinely 
done for the same purpose, consists of using antibodies directed against von 
Willebrand factor (vWF) (1:200; Sigma-Aldrich, St-Louis, MO), which is known 
to be produced constitutively by endothelial cells, but not by the underlying 
cardiomyocytes or smooth muscle cells (DATTA and EWENSTEIN, 2001; VAN 
MOURIK et al, 2002). Using secondary rabbit anti-IgG antibodies conjugated to 
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Alexa Fluor 488 (1 ug/ml; Molecular Probes, Eugene, OR) followed by the 
technique of indirect immunofluorescence described in section 2.3. vWF was 
found to be present throughout the cytosol of EECs in a particulate manner. 
2.2 PretreatmentofEECs 
2.2.1 Studies for the effect of extracellular NPY on the intracellular ET-1 
fluorescence intensity in EECs 
For immunofluorescence studies, REECs and LEECs cultured on 25 mm 
coverslips, in the presence of medium Ml99 and 10% FBS, were incubated at 
37°C and 5% CO2 for 24 hours. Following the 24-hour incubation period, EECs 
were exposed to different concentrations of neuropeptide Y (NPY), in the absence 
and presence of different NPY and ET-1 receptor antagonists (Table 1), for time 
intervals of 5, 10, 20, 30 and 60 minutes at 37°C. At the end of the pretreatment 
period, NPY or NPY+ antagonist were washed from the extracellular medium and 
cells were fixed with 4% paraformaldehyde (PFA) in order to perform indirect 
immunofluorescence (described in section 2.3). 
2.2.2 Studies for the effect of extracellular NPY on the secretion of ET-1 
from EECs 
For studies of the effect of NPY on the secretion of ET-1, REECs and 
LEECs cultured in 100 mm Petri dishes, in the presence of medium Ml99 and 
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10% FBS, were incubated at 37°C and 5% CO2 until confluence was reached. 
Upon confluence, EECs were exposed to NPY (10"7M), in the absence and 
presence of different NPY and ET-1 receptor antagonists (Table 1), for time 
intervals of 5, 10, 20, 30 and 60 minutes at 37°C. At the end of each incubation 
period, 600 ul of the culture medium were collected to determine the concentration 
of ET-1 secreted by EECs using ELISA (described in section 2.5). EECs were then 
washed with phosphate-buffered saline (PBS; IX, pH 7.4) 3 times, gently scraped 
in the presence of 600 ul of serum-free medium Ml99 and the cell lysate was 
finally collected. The collected samples of media and cell lysates were conserved 
at -80°C for ELISA to be performed later on. It should be mentioned that the PBS 
IX used had the following composition: NaCl, 136 mM; KC1, 2.68 mM; 
Na2HP04, 10.14 mM; KH2P04, 1.76 mM. 
It is also worth noting that the NPY used in all of the experiments is of 
human origin, and was kindly supplied by Dr Alain Fournier (INRS-Sante, 
Universite de Quebec, Pointe-Claire, QC). 
2.3 Indirect immunofluorescence 
The technique used throughout this study was modified from Brismar et al. 
(1998). Briefly, REECs and LEECs, cultured on 25 mm coverslips and treated 
with NPY (in the absence and presence of specific antagonists as described 
earlier), were subjected to 2 rapid washes with PBS (IX, pH 7.4). This was 
followed by a fixation period of 10 minutes with 4% PFA (Cedarlane, Hornby, 
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Table 1. List of the different NPY and ET-1 receptor antagonists used for the 
pretreatment of endocardial endothelial cells. 
Antagonist BIBO3304 BIIE0246 L-152,804 ABT-627 A192621 
Corresponding 
receptor 
Peptidic 
Non-peptidic 
Working 
concentration 
Provider 
Y,R 
antagonist 
No 
Yes 
10"6M 
Gift from 
Boehringer 
Ingelheim, 
Parma KG, 
Germany 
Y2R 
antagonist 
No 
Yes 
10"6M 
Y5R 
antagonist 
No 
Yes 
1(T6M 
Tocris Bioscience, 
Ellisville, MO, USA 
ETAR 
antagonist 
No 
Yes 
10~7M 
ETBR 
antagonist 
No 
Yes 
10~7M 
Gift from Dr. Pedro 
D'Orleans-Juste 
(Pharmacology dept., 
Faculty of medicine, 
University of 
Sherbrooke) 
Note: The concentration of NPY used with all of the above-mentioned antagonists 
is 10"7M. 
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ON). Cells were then washed twice with PBS (IX, pH 7.4), the duration of each 
wash being 5 minutes, and incubated with a solution of sodium borohydride 
(2mg/ml) (Sigma-Aldrich, St-Louis, MO), the purpose of which is to neutralize the 
aldehyde groups. This was followed by 2 washes with PBS (IX, pH 7.4) for 5 
minutes each. In order to permeabilize our cells and block the sites of non-specific 
binding, EECS were incubated for 30 minutes with a solution of 0.1% (v/v) of 
Triton X-100 containing 7% (v/v) of normal goat serum (NGS) (Sigma-Aldrich, 
St-Louis, MO) and 5% (m/v) of non-fat dried milk (NFDM) (Sigma-Aldrich, St-
Louis, MO). After 2 washes with PBS (IX, pH 7.4), EECs were incubated 
overnight at 4°C with the primary antibody which was diluted in a solution of 
0.1 % (v/v) of Triton, containing 1.4% (v/v) of NGS and 1 % (m/v) of NFDM. It is 
worth noting that the processes of fixation, permeabilization and saturation were 
all carried out at room temperature (RT). 
Following the overnight incubation with the primary antibody, EECs were 
washed twice with PBS (IX, pH 7.4) for 5 minutes each time, and then incubated 
in the dark for 1 hour at RT with the secondary antibody which is conjugated to a 
fluorescent probe, the fluorophore 488, and diluted in a solution of 0.1% (v/v) of 
Triton, containing 1.4% (v/v) of NGS and 1% (m/v) of NFDM (BRISMAR et al, 
1998). Finally, EECs were washed twice with PBS (IX, pH 7.4) and visualized 
using the confocal microscope. 
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2.3.1 Endothelin-1 labeling 
Using the technique of indirect immunofluorescence, ET-1 in human 
REECs and LEECs was labeled with a specific primary mouse monoclonal 
antibody raised against human ET-1 (Biodesign International, Saco, ME, USA) at 
a dilution of 1:100 (stock concentration is 1 mg/ml). The secondary antibody used 
is a rabbit Alexa Fluor 488-conjugated antibody raised against mouse IgG with a 
concentration of 1 ug/ml (stock concentration is 2 mg/ml; Molecular probes, 
Oregon, USA) (JACQUES et ai, 2005). To ensure the specificity of the obtained 
ET-1 labeling, 2 different negative controls were carried out. In the first, the 
primary anti-ET-1 antibody was preadsorbed with an excess of ET-1 (10°M; 
Bachem Bioscience Inc., King of Prussia, PA) for 3 hours before carrying out the 
overnight incubation of the cells with the primary antibody. In the second negative 
control, the primary antibody was omitted and thus cells were incubated with the 
secondary antibody alone. 
2.4 Confocal microscopy 
Confocal microscopy is an optical imaging technique which has been 
gaining a lot of popularity in the scientific community. This technique is used 
routinely in our lab because it offers significantly more advantages when 
compared to conventional fluorescence microscopy. One of the many advantages 
of this technique is that it allows the generation and 3-D reconstruction of serial 
optical images by scanning of a biological specimen, while at the same time 
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eliminating out-of-focus light by using an interplay between mirrors and a pinhole 
(aperture) incorporated within the system (NIGGLI and LEDERER, 1990; LIPP 
and NIGGLI, 1993; NIGGLI et ai, 1994; BKAILY et ai, 1996; BKAILY et ai, 
1997). This ability to eliminate out-of-focus light results in another advantage of 
the confocal microscope which is the generation of high-quality images with a 
resolution approximately 30% higher than the conventional microscope. Yet a 
third advantage of confocal microscopy is the fact that it allows the visualization 
of a biological specimen's interior (e.g. subcellular structural detail) and the 
comparison of fluorescence intensity levels of different compartments (NIGGLI et 
ai, 1994). 
The system of confocal microscopy which was used in this study is the 
Multiprobe 2001 argon laser scanning confocal microscopy (Molecular Dynamics, 
Sunnyvale, CA) (LSCM) system equipped with a Nikon Diaphot epifluorescence 
inverted microscope and a 60 x (1.4NA) Nikon Oil Plan achromat objective. 
2.4.1 Principle of confocal microscopy 
In order to reach the sample, which is found in a plane called the focal 
plane, the excitation laser beam is directed by the microscope lens towards a given 
point of the sample called the focal point belonging to the focal plane (Figure 7). 
The light reflected from the focal point is then directed (while following the same 
path as that of excitation) through the microscope's different optical compartments 
comprised of mirrors and optical filters, all of which converge this light beam to a 
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second point called the confocal point. A system of shutters or 'openings', located 
at the level of the confocal point, will then block all incident light stemming from 
points that lie above or beneath the focal plane, namely out-of-focus light. In this 
way, only light arising from the focal point will be allowed to pass through the 
confocal point to be consequently detected by the microscope's photomultiplier 
tube (PMT); and this, in fact, is what gives images generated by the confocal 
microscope their exceptional resolution and clarity (Manual of the Multi probe 
2001 microscope). 
2.4.2 Scanning of cells in 3 dimensions 
Being able to visualize a cell is an essential part of cell biology. Confocal 
microscopy, therefore, is a major advancement in this field since, not only does it 
allow us to see deep into cells, but also to visualize the dynamics of cellular 
processes and then to recreate a 3-D representation of that. A confocal microscope 
allows the collection of optical slices of a cell, or biological specimen in general, 
by changing the level or plane (focal plane) in which the sample is being 
visualized. When the focal plane is changed, a series of images at different 
positions can be produced across the thickness (Z) of the sample, i.e. a series of X-
Y images at different Z positions is generated. This series or stack of optical 
images can then be used to produce a 3-D reconstruction of the sample being 
observed. The reason for the serial sectioning or scanning is that only one point is 
illuminated at a time when using a confocal microscope. So to be able to obtain a 
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3-D reconstruction of the sample being studied, the latter has to be scanned from 
side to side in lines from top to bottom. 
In our LSCM, the 488-nm argon laser line (9.0 mV) was directed to the 
sample via a 510-nm primary dichroic filter and attenuated with a 1-3% neutral-
density filter to reduce photobleaching. Pinhole size, image size, pixel size and 
step size were set to 50 urn, 512x512 pixels, 0.34 urn and 0.5 urn, respectively. 
Laser line intensity, photometric gain, PMT settings and filter attenuation were 
kept constant throughout the experimental procedures (BKAILY et ai, 1997; 
JACQUES etal, 2000a). 
The serial, Z-axis optical scans (section series) taken for cells are captured 
by a photodetector, digitalized and saved. Using the image processing software, 
Imagespace, the captured section series can then be presented either as 2-D or 3-D 
reconstructions using various angles of rotation and inclination as well as a variety 
of cutting planes. These 3D reconstructions of cells are then used for the 
measurement of basal-level fluorescence intensity and/or the cellular response 
after the addition of different agents (BKAILY et ai, 1997). 
2.4.3 Nuclear Staining 
At the end of each experiment, the nucleus was stained with 100 nM of the 
live nucleic acid stain (sytoll) (Molecular Probes, Eugene, OR). Serial Z-axis 
optical scans were taken after development of the stain (3-5 minutes) while 
maintaining positioning, number of sections and step size identical to those used 
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throughout the experiment. Nuclear labeling is important because it permits the 
isolation or extraction of the nucleus from the cytoplasm by setting a lower 
intensity threshold filter to confine relevant pixels (BKAILY et ai, 1997; 
JACQUES et ah, 2003b). Fluorescence intensities can then be measured in the 
entire volume of each compartment (cytosol and nucleus) separately to provide 3-
D information (BKAILY et al, 2003b). 
2.4.4 Volume rendering and fluorescence intensity measurement 
Scanned images were transformed onto a Silicon Graphics O2 analysis 
station equipped with Molecular Dynamics Imagespace 3.2 analysis and volume 
workbench software modules. Reconstruction of 3-D images was performed on 
unfiltered serial sections. All 3-D reconstructions were then presented using the 
'maximum intensity', 'look through' and 'surface plot' (fish net) projection 
modes, all of which are just different representations of a 3-D image using the 
Imagespace software. For example, the 'surface plot' mode is a topographical 
distribution of the fluorescence intensity levels all over the cell, whereas the 'look 
through' mode depicts a cell as if it were transparent while being in focus 
throughout its depth and is very useful for studying interior features and details. It 
is worth noting that immunofluorescence images were presented as pseudocolored 
representations according to an intensity scale of 0-255, with 0 intensity in black 
indicating absence of fluorescence and 255 in white indicating maximal 
fluorescence intensity (BKAILY et al., 1999). 
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The 3-D reconstructions (section series) of cells were used for the 
measurement of whole-cell fluorescence intensities where cells were simply 
delimited. However, when the measurement of the nuclear and cytosolic 
fluorescence intensities is needed to be done separately, the nuclear area 
(following syto 11 staining) is isolated from the rest of the cell by setting a lower 
intensity threshold filter to confine relevant pixels. A 3-D binary image series of 
the nuclear volume is then generated for each cell, using the exact same x, y and z 
set planes as those used for immunofluorescence labeling. Thus, by applying these 
binary image patterns, which now serve as a cookie cutter, to their corresponding 
cells (but labeled for a specific ion, peptide or receptor), 2 new 3D projections are 
created depicting fluorescence intensity levels in the nucleus and cytosol 
separately (BKAILY et ai, 1997; JACQUES et al., 2003b). Intensities can then be 
measured in the entire volume of sections for each compartment (cytosol and 
nucleus) to provide 3D information. Since our measurements are done over the 
whole volume of the cell, and not in one or a few sections for the entire cell 
volume, they eliminate any possible problem concerning drifting of the Z-line 
(BKAILY et a!., 2003b). 
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2.5 Enzyme-linked immunosorbent assay (ELISA) 
2.5.1 Principle 
The ELISA kit used throughout the study is the Endothelin-1 Biotrak™ 
ELISA System provided by Amersham Biosciences (GE Healthcare Biosciences 
AB, Uppsala, Sweden). Each kit contains sufficient material for 96 wells and 
permits the construction of one standard curve and 40 unknowns in duplicate. All 
the solutions and reagents necessary for carrying out an experiment are provided 
with the kit with the exception of the stop solution, namely sulfuric acid (H2SO4). 
This assay is based on a 'sandwich' format. Standards and samples are incubated 
in the wells precoated with antibody against ET-1. Any ET-1 present in the 
standards or samples will be bound to the antibody in the wells, other components 
of the samples being removed by washing and aspiration. The bound ET-1 is 
detected using a Horseradish Peroxidase (HRP)-labeled Fab' fragment of ET-1 
antibody conjugate (Figure 8). The concentration of antibody conjugate bound to 
each well is determined by the addition of tetramethylbenzidine (TMB) substrate. 
The reaction is finally stopped by the addition of H2SO4 and the resultant color 
read at 450 nm in a microplate spectrophotometer. The concentration of ET-1 in 
the samples is determined by extrapolation from the standard curve. This kit 
allows for the determination of ET-1 in the range of 1-32 fmol/well (24.8-797.4 
pg/ml). The cross-reactivity of this kit with other related compounds is shown in 
Table 2 (Manual of the 'Endothelin-1 Biotrak ELISA system'). 
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Table 2. Cross-reactivity of the endothelin-1 ELISA kit with a number of ET-
1 related compounds. 
Compound 
Endothelin-1 (synthetic) 
Endothelin-2 (synthetic) 
Endothelin-3 (synthetic) 
Big endothelin-1 (human) 
Big endothelin 22-38 (human) 
Big endothelin-1 (porcine) 
Big endothelin 22-39 (porcine) 
Atrial natriuretic peptide (human, synthetic) 
BNP (porcine, synthetic) 
Sarafotoxin S6b 
Vasoactive intestinal contractor (mouse) 
% Cross-reactivity 
100 
<0.00003 
<0.00003 
<0.00002 
<0.00005 
0.0001 
<0.00002 
<0.00007 
<0.00007 
<0.00003 
<0.00003 
(Adapted from the manual of the 'Endothelin-1 Biotrak ELISA system') 
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2.5.2 Assay protocol 
The procedure was carried out exactly as described by the manufacturer. 
All reagents needed for performing the ELISA experiments were always prepared 
before starting. These are: assay buffer, wash buffer, working standards and 
antibody conjugate. The TMB substrate is provided in a 'ready-to-use' form. It 
should be noted that working standards were freshly prepared before each assay 
and never reused, and that standards and samples were always run in duplicate. 
The ET-1 standard provided with the kit has a stock concentration of 320 fmol/ml 
(32 fmol/well) and is used for the preparation of 5 working standards with the 
following concentrations: 1, 2, 4, 8 and 16 fmol/well. Briefly, 
> 100 ul of assay buffer were pipetted into the zero standard (non-specific 
binding: NSB) wells. 
> 100 ul of each standard and sample (collected as described in section 2.2.2) 
were pipetted into the appropriate wells and the plate was then covered with 
the lid provided, gently mixed and incubated at 3-5°C overnight. 
> All wells were aspirated and washed 4 times with 400 ul of wash buffer and 
the plate was blotted on absorbent paper to ensure that any residual fluid was 
removed from the bottom of the wells. 
> 100 ul of antibody conjugate were added to all wells except the blank and the 
plate was covered again and incubated at 37°C for exactly 30 minutes. 
-74 -
> All wells were aspirated and washed 4 times with 400 ja 1 of wash buffer and 
the plate was blotted on absorbent paper to ensure that any residual fluid was 
removed from the bottom of the wells. 
> 100 ul of room temperature-equilibrated TMB substrate were immediately 
added into each well. The plate was covered and mixed on a shaker for exactly 
40 minutes at RT. A blue color developed which was read at 630 nm. 
> 100 ul of 1.0 M H2SO4 were added into each well, the contents were mixed 
and the optical density determined using a spectrophotometer at 450 nm within 
30 minutes. 
(Manual of the 'Endothelin-1 Biotrak ELISA system'). 
2.6 Statistics 
Results relating to the indirect immunofluorescence experiments were 
presented as mean intracellular fluorescence intensity values of ET-1 ([ET-1 JO, 
whereas those relating to the ELISA experiments were presented as the mean 
concentration of ET-1 (in pg/ml) in the extracellular medium. All values are 
expressed as means + S.E.M (standard error of the mean), where 'n' represents the 
number of cells in 'N' different experiments. Statistical significance was 
determined using the Student's t test, where a p value < 0.05 was considered as 
significant. 
-75-
III. RESULTS 
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3.1 Specificity of ET-1 labeling in human EECs 
Secretion of ET-1 from human EECs (hEECs) was measured as a decrease 
in the whole-cell intracellular fluorescence intensity of ET-1 using the technique 
of indirect immunofluorescence. To ensure the specificity of the obtained ET-1 
labeling, 2 different negative controls, shown in Figure 9, were performed. In both 
controls, the same protocol of indirect immunofluorescence was applied but with a 
change in the step of the overnight incubation with the primary antibody. In the 
first control (Figure 9a), cells were incubated overnight with primary antibody 
(directed against ET-1) which was preadsorbed with an excess of ET-1 (10"5M), 
whereas in the second control (Figure 9c), cells were incubated overnight with 
omission of the primary antibody. As can be observed from Figure 9, there is no 
fluorescence signal in both panels a and c, which confirms the specificity of both 
the primary and secondary antibodies used. 
3.2 Effect of the extracellular administration of increasing 
concentrations of NPY (101 5 , 10"10 and 10°M) on the fluorescence 
intensity of ET-1 in hEECs 
As mentioned in the last part of the chapter 'Introduction', the hypothesis 
proposed for the current study is the existence of a dialogue between the systems 
of NPY and ET-1 at the level of hEECs. As an important part of this dialogue, we 
wanted to investigate if NPY is able to stimulate or modulate the secretion of ET-1 
from right and left ventricular hEECs. In order to study this secretory effect of 
- 7 7 -


NPY on ET-1, we used the techniques of indirect immunofluorescence with a 
monoclonal antibody directed against ET-1 coupled to 3-D confocal microscopy, 
as well as the technique of ELISA as a confirmation of ET-1 secretion (if there is 
any). We proceeded, as a first series of experiments, by subjecting cultured hEECs 
to increasing concentrations of extracellular NPY (1(T15M, 10~,0M and 10"SM) for 
time intervals of 5, 10, 20, 30 and 60 minutes at 37°C. A control sample was 
always performed in which EECs were not subjected to any NPY but just 
underwent a change of medium. After the pretreatment of EECs with NPY, 
indirect immunofluorescence was performed on the samples which were finally 
visualized with a confocal microscope to examine if NPY is able to modulate the 
fluorescence intensity of ET-1 in these cells; a phenomenon which could indicate 
secretion if the result is a decrease in the intensity of labeling of ET-1. It should be 
mentioned that throughout this study, an example of hEECs in control condition 
and another of hEECs after 60 minutes of exposure to the various treatment 
protocols used were chosen as representations for the different confocal 
microscopy experiments. 
3.2.1 REECs 
3.2.1.1 Effect of a very low concentration of extracellular NPY (10"15M) on the 
whole-cell fluorescence intensity of ET-1 in hREECs 
Previous results recently obtained by our group (SADER, 2002; JACQUES 
et al, 2003b) demonstrated that only the right human ventricular endocardial 
-80-
endothelial cells (hREECs) are able to secrete NPY into the extracellular medium 
following the stimulation with a sustained high concentration of KG (30 mM), a 
concentration known to depolarize and induce a sustained rise in the [Ca2+]j 
(BKAILY et ai, 1997; JACQUES et ai, 2000a; JACQUES et ai, 2003b), for 
periods of 5, 10, 20, 30 and 60 minutes. These results were confirmed using both 
3-D confocal microscopy as well as radioimmunoassay (RIA). Based on these 
results, we first proceeded with the protocol mentioned above in section 3.2 by 
using hREECs and subjecting these cells to NPY (10"15M) for time intervals of 5, 
10, 20, 30 and 60 minutes, in an attempt to examine the effect of this NPY 
concentration on the intracellular fluorescence intensity of ET-1. Figure 10 shows 
a representative example of this series of experiments. As it can be observed in 
this figure, there is a significant decrease in the intracellular fluorescence intensity 
of ET-1 after 60 minutes (Figure 10 d, e and f) of REEC exposure to 10 15M of 
NPY when compared to the cell in control conditions (Figure 10 a, b and c). This 
decrease can be seen throughout the entire cell especially at the level of the cytosol 
(including the plasma membrane) where it is somewhat difficult to depict the 
border or outline of the cell in certain areas of this membrane (Figure 10 d, e and 
f). A cell, whether in control condition or after 60 minutes of NPY exposure, was 
displayed using 3 different modes of presentation, a manipulation which is made 
possible through the use of the image analysis software, Imagespace. In order to 
see the total 3-dimensional distribution and intensity of the ET-1 labeling, cells 
were reconstructed in 3-D using 'the top view, maximum intensity' mode (Figure 
10 a and d). For more appreciation of internal structure and detail, cells were 
reconstructed in 3-D using the 'look-through' mode (Figure 10 b and e). Finally, to 
-81 -

M
ax
im
um
 
In
te
ns
ity
 
Lo
ok
 
Th
ro
ug
h 
Su
rfa
ce
 
Pl
ot
 
,
 
i,
 
•
 
—
—
-
—
 
^
2
5
5 
be able to better visualize the amplitude of change as well as the difference in the 
level of ET-1 fluorescence intensity between control conditions and following 60 
minutes of NPY exposure, cells were presented using the 'surface plot' mode 
(Figure 10 c and f) which is a topographical distribution of the ET-1 density in the 
different cellular compartments taken from the 3-D reconstruction of the cell in 
'maximum intensity' mode. 
3.2.1.2 Effect of a high extracellular concentration of NPY (10"10M) on the 
whole-cell fluorescence intensity of ET-1 in hREECs 
Having observed the effect of a very low concentration of NPY (10~15M) 
on the fluorescence intensity of ET-1 in hREECs, we proceeded next to examine 
the effect of a more pathological concentration of NPY, namely 10~10M. Again, 
hREECs were exposed to 10"10M of NPY for 5, 10, 20, 30 and 60 minutes, after 
which time the confocal microscope was used to visualize any change in density of 
ET-1 in hREECs over the different time intervals listed above. As can be observed 
from Figure 11, there is a decrease in the intracellular fluorescence intensity of 
ET-1 in hREECs treated with NPY (10 10M) for 60 minutes (Figure 11 d, e and 0 
as compared to the control (Figure 11 a, b and c). It is worth noting that just by 
observing the images in Figure 10 and Figure 11, it can be perhaps said that the 
decrease in the intensity of labeling of ET-1 seen with NPY (10~10M) is to a 
slightly lesser degree than that which was seen using NPY (10"15M), for the outline 
of the cell in most areas of the plasma membrane in Figure 11 can still be 
delineated easier than that in Figure 10. 
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NPY(10-10M) 
60 min Control 
3.2.1.3 Effect of a very high extracellular concentration of NPY (10"5M) on the 
whole-cell fluorescence intensity of ET-1 in hREECs 
Using the same protocol described in section 3.2, we tested the effect of 10" 
M NPY on the intracellular fluorescence intensity of ET-1 in hREECs again after 
exposing these cells for 5, 10, 20, 30 and 60 minutes to the above-mentioned NPY 
concentration. Figure 12 shows a representative experiment. As can be seen in this 
figure, we can clearly observe a remarkable decrease in the density of ET-1, when 
comparing a hREEC in the absence (Figure 12 a, b and c) and following 60 
minutes of exposure to 10"5M of NPY (Figure 12 d, e and f). Note the high 
intensity of ET-1 labeling throughout the cytosol (including the plasma membrane) 
as well as the nucleus of the control hREEC (a, b and c) and the strong decrease of 
ET-1 fluorescence in the 60-minute REEC (d, e and 0, particularly throughout the 
cytosol; an observation which can be made due to the abundance of low-signal 
(dark blue) as well as absence-of-signal (black) areas. Moreover, note the fine ET-
1 labeling on the plasma membrane of the cell after 60 minutes of treatment with 
10"5M of NPY (d, e and f), a phenomenon which could indicate high activity 
surrounding that area (perhaps secretion). It should be mentioned that the 'surface 
plot' images (c and f) of REECs in this series of experiments were presented with 
a rotation of 70° (c) and 30° (f) simply to get a better or a different view of the ET-
1 labeling (especially the nuclear labeling) from a different angle. 
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NPY(10"5M) 
60 min Control 
3.2.1.4 Measurements of the relative density (by um3) of whole-cell ET-1 in 
hREECs following exposure to increasing concentrations of NPY (1013 - 10" 
5M) 
Scanned images of EECs were transferred onto an analysis station 
equipped with an image processing software where 3-D reconstructions of the 
cells were used for semiquantitative measurements of the ET-1 whole-cell 
fluorescence intensity. To provide 3-D information which is as close as possible to 
reality, measurements were performed over the entire cell volume (BKAILY et ah, 
2003b). 
As it can be observed from Figure 13A, treatment of hREECs with 10"15M 
of NPY induced a significant, time-dependent decrease in the relative density of 
ET-1 starting at 5 minutes after treatment with NPY. The intracellular ET-1 
fluorescence intensity (by urn) measurements in hREECs at the control level and 
at the different time intervals of exposure to NPY (10"15M) are as follows: control 
value is 6.834 + 0.332, n = 30; 5 minute value is 5.675 ± 0.342, n = 20; 10 minute 
value is 5.747 ± 0.354, n = 17; 20 minute value is 5.685 + 0.259, n = 20; 30 minute 
value is 5.581 + 0.281; n = 26 and the 60 minute value is 5.441 + 0.278, n = 25. 
Looking at Figure 13B, it can be observed that with a high concentration of 
NPY of 10"1 M, there is a significant decrease (p < 0.05) in the relative density of 
ET-1 in hREECs only after 60 minutes of exposure to NPY (7.030 ± 0.399, n = 26 
as compared to the control : 8.300 + 0.475, n = 24). 
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Fluorescence intensity measurements of whole-cell ET-1 were also done 
for experiments using a very high concentration of NPY (10"5M) (Figure 13C). 
Interestingly and different to what was observed with 10~10M NPY, a very high 
level of this peptide (1CPM) induced a significant decrease in the intensity level of 
ET-1 at 20 minutes of hREEC treatment (7.202 ± 0.591, n = 19 as compared to 
the control: 9.506 + 0.640, n = 18). This significant decrease continued and 
became more pronounced at 30 and 60 minutes of treatment with 10" M NPY (the 
30 minute and 60 minute values are respectively: 6.866 + 0.473, n = 21 and 5.833 
±0.311, n = 23). 
3.2.2 LEECs 
3.2.2.1 Effect of a very low concentration (lO^M) of extracellular NPY on the 
whole-cell fluorescence intensity of ET-1 in hLEECs 
Using the same protocol as in section 3.2, we tested the effect of a low 
concentration of NPY on left ventricular hEECs. Figure 14 shows a representative 
example of LEECs in the absence (a, b and c) and at 60 minutes of exposure to 10" 
15M of NPY (d, e and f). As can be seen in this figure, there is an apparent 
decrease in the whole-cell fluorescence intensity of ET-1 especially at the 
cytosolic level when compared to the cell in control conditions. Moreover, the 
LEEC in control conditions (a, b and c), as well as that at 60 minutes of NPY 
exposure (d, e and f), were displayed using the 3 different modes of presentation 
- 9 3 -

NPY(1015M) 
60min Control 
described earlier in section 3.2.1.1 using the image analyzing software 
'Imagespace\ 
3.2.2.2 Effect of a high extracellular concentration of NPY (10'10M) on the 
fluorescence intensity of ET-1 in hLEECs 
Always following the same treatment protocol of 5, 10, 20, 30 and 60 
minutes of exposure to NPY, we proceeded to treat hLEECs with 10"10M of NPY 
and examine its effect on the whole-cell fluorescence intensity level of ET-1. 
Surprisingly, and in contrast to what was obtained with hLEECs treated with a 
very low concentration of NPY (10"15M) and to hREECs treated with a high 
concentration (10"10M NPY). it can observed from Figure 15 that there is no 
noticeable difference in the intensity of labeling of ET-1 when comparing the 
LEEC in control conditions (a, b and c) to that after 60 minutes of exposure to 
N P Y a t l 0 , 0 M ( d , eandf)-
3.2.2.3 Effect of a very high extracellular concentration of NPY (10°M) on the 
fluorescence intensity of ET-1 in hLEECs 
Similar to REECs, hLEECs were treated with NPY at a very high 
concentration of 10 M for 5, 10, 20, 30 and 60 minutes at 37 °C. Figure 16 shows 
that once again, there is an apparent decrease in the fluorescence intensity of ET-1 
after 60 minutes of hLEEC exposure to 10"5M of NPY, an effect which seems to 
be more pronounced at the cytosolic level owing to the abundance of 'low-signal' 
and 'lack-of-signal' areas. 
-96-

NPY(10-10M) 
60min Control 

NPY(10"5M) 
60 min Control 
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3.,2.2.4 Measurements of the relative density (by u.m3) of whole-cell ET-1 in 
hLEECs following exposure to increasing concentrations of NPY (10"15 - 10" 
5M) 
Assessments of the ET-1 fluorescence intensities (by jam1) in hLEECs were 
performed using 3-D reconstructions of cells that have undergone treatment with 
NPY (10 l5M, 10~'°M and 10"3M) for the different time intervals described in 
section 3.2. It can be observed from Figure 17 that both a very low (10 15M) (panel 
A) as well as a very high (10"5M) (panel C), but not a relatively high (10~10M) 
(panel B), concentration of NPY caused a significant decrease in the relative 
density of ET-1, but one which was observed only at 60 minutes of LEEC 
treatment with these 2 concentrations. 
The relative ET-1 fluorescence intensity measurements obtained at the 
control level and after 60 minutes of hLEEC treatment with NPY (10"15M) are as 
follows: control value is 6.268 ± 0.269, n = 35 and the 60 minute value is 5.418 ± 
0.257, n = 32. 
As for 10"5M of NPY, the relative density measurements of ET-1 obtained 
in hLEECs at the control level and following 60 minutes of treatment with the 
above-mentioned NPY concentration are as follows: control value is 7.013 + 
0.208, n = 30 and the 60 minute value is 6.423 ± 0.175, n = 33. 
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3.2.3 Comparison of the response of hREECs as compared to that of 
hLEECs upon stimulation with increasing concentrations of NPY (1015 - 10" 
5M) 
As part of the objectives of the current study, we wanted not only to 
examine if hREECs and hLEECs respond to NPY stimulation with a decrease in 
the fluorescence intensity of ET-1 (which suggests secretion), but also if there are 
any differences between the responses of the right and left ventricular hEECs. 
Sections 3.2.1 and 3.2.2 showed that NPY at concentrations of 10"15M, 10~10M and 
10"5M had an effect on the level of fluorescence intensity of ET-1 in both hREECs 
as well as hLEECs. In this section, this NPY-induced effect is compared between 
hREECs and hLEECs at 60 minutes of exposure to the 3 concentrations of NPY 
mentioned above. It can be observed from Figure 18A that the response, which is a 
decrease in ET-1 fluorescence intensity, is similar in hREECs (79.620% ± 4.067, n 
= 25) as compared to hLEECs (86.438% ± 4.107, n = 32) at 60 minutes of 
treatment with NPY (10"15M). However, at 10 10M of NPY (Figure 18B), the NPY-
induced decrease in ET-1 fluorescence intensity is more pronounced in hREECs 
(84.699% ± 4.807, n = 26) as compared to hLEECs which hardly show any 
response (98.397% ± 3.437, n = 55). As to 10"5M of NPY (Figure 18C), the 
response becomes much more pronounced and highly significant in hREECs 
(61.363% ± 3.269, n = 23) as compared to hLEECs (91.587% ± 2.489, n = 33). 
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3.3 Effect of NPY on the extracellular level of ET-1 in hREECs and 
hLEECs 
So far, we have seen the effect of extracellular NPY on the intracellular 
level of ET-1 in hREECS and hLEECs; and as the previous sections demonstrated, 
NPY was able to dose- and time- dependently induce a decrease in the density of 
[ET-1 ]; at the level of both the right and left ventricular hEECs. However, in order 
to ensure that this NPY-induced decrease in the intracellular level of ET-1 is 
indeed secretion, the technique of ELISA was used to examine if the above-
mentioned decrease is accompanied by an increase in the extracellular level of ET-
1. For this purpose, cultured hEECs isolated from both the right and left ventricles 
of human hearts were exposed to NPY (10"7M) for intervals of 5, 10, 20, 30 and 60 
minutes and samples of the extracellular medium were collected after each time 
period to determine the extracellular concentration of ET-1 by ELISA. Since 
secretion is a calcium-dependent phenomenon, and since our previous results 
showed that treatment of hREECs and hLEECs with NPY (10"15M - 10"3M) 
induced a rise in the [Ca2+]i that reached a plateau at 10"6M (SADER, 2002), thus a 
concentration of 10" M of NPY was chosen here for confirmation of ET-1 
secretion. 
At the level of hREECs, Figure 19 shows that exposure of these cells to 10" 
7M of NPY for time intervals of 5, 10, 20, 30 and 60 minutes resulted in an 
increase in the extracellular concentration of ET-1. This rise became significant at 
60 minutes of treatment with NPY (17.612 pg/ml ± 3.226) as compared to the 
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control level (4.50 pg/ml + 0.896). 
Similarly, 10~7M of NPY induces a significant rise in the extracellular level 
of ET-1 at 60 minutes of hLEEC exposure to NPY (Figure 20) (control level [ET-
1J0: 3.612 pg/ml ± 1.148; 60 minute [ET-1J0: 15.021 pg/ml ± 3.032). 
These results clearly suggest that the NPY-induced decrease in the [ET-1]; 
fluorescence intensity in both hREECs and hLEECs is indeed due to secretion of 
the latter into the extracellular medium. 
3.4 Role of the NPY receptors, Y1? Y2 and Y5, in the NPY-induced 
secretion of ET-1 in hREECs and hLEECs 
In this series of experiments, we investigated if the activation of NPY 
receptors, Yi and/or Y2 and/or Y5 is implicated in the ET-1 secretory response of 
hREECs and hLEECs to stimulation with NPY. 
3.4.1 Effect of blockade of the Yi receptor on the NPY-induced secretion of 
ET-1 in hREECs and hLEECs 
Our group has recently demonstrated the presence of NPY and its Yi 
receptor at the level of hREECs and hLEECs (SADER, 2002; JACQUES et ah, 
2003b). In order to examine if this receptor is implicated in the NPY-induced 
decrease of [ET-1 J; as well as the NPY-induced increase of [ET-1]0 at the level of 
both hREECs and hLEECs, we used the highly-selective, non-peptidic Yi receptor 
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antagonist, BIBO3304 (WIELAND et al., 1998; DUMONT et al, 2000a; 
DUMONT <* a/., 2000c). 
3.4.1.1 Effect of blockade of the Yt receptor on the NPY-induced decrease of 
ET-1 fluorescence intensity in hREECs and hLEECs 
To investigate the implication of the Yi receptor in the NPY-induced 
decrease of the ET-1 fluorescence intensity in hEECs, cultured hREECs and 
hLEECs were first incubated for 15 minutes with the Yi receptor antagonist, 
BIBO3304, at a concentration (10~6M) which is known to completely block this 
type of receptor (DUMONT et al, 2000a; DUMONT et al, 2000c). After this, and 
in presence of the antagonist, NPY (10"7M) was added for 5, 10, 20, 30 and 60 
minutes. A control sample, where EECs were incubated with the Yi receptor 
antagonist alone for 15 minutes was always performed. 
In hREECs, it can be observed from Figure 21 that blockade of the Yi 
receptors did not prevent a 60 minutes treatment with NPY from inducing a 
decrease in the ET-1 fluorescence intensity seen at the level of the cytosol of 
hREECs. Similarly, BIBO3304 (10"6M) did not prevent NPY (10"7M) from 
inducing a decrease in the intensity of fluorescence of ET-1 at the level of hLEECs 
(Figure 22). 
Measurements of the relative density of ET-1 (by urn") in hREECs and 
hLEECs exposed to NPY in the presence of the Yi receptor antagonist were taken 
and these values were compared to those obtained before using NPY alone at 10~ 
5M (section 3.2.1.4 for REECs and 3.2.2.4 for LEECs). It can be observed from 
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Figure 23 that in the presence of the Yi receptor antagonist, BIBO3304, the 
decrease in the level of ET-1 fluorescence intensity starts to become significant at 
10 minutes of hREEC (Figure 23A) and hLEEC (Figure 23B) treatment with NPY 
as compared to its respective control (control hREEC: 8.706 ± 0.369, n = 44; 10 
minutes hREEC: 7.021 ± 0.242, n = 54; control hLEEC: 6.883 ± 0.212, n = 34; 10 
minutes hLEEC: 6.031 ± 0.20, n = 35). This decrease continues up till 60 minutes 
of treatment with NPY in both types of cells (hREECs: 20 minute value is 7.118 ± 
0.286, n = 51; 30 minute value is 6.281 + 0.269, n = 45 and the 60 minute value is 
5.931 ± 0.224, n = 42; hLEECs: 20 minute value is 6.154 + 0.16, n = 29; 30 
minute value is 6.09 + 0.187, n = 46 and the 60 minute value is 5.232 + 0.185, n = 
34). 
Thus, by looking at panels A and B of Figure 23, it can be observed that 
blockade of the Yi receptor (bars in red) did not prevent at all the NPY-induced 
decrease in the density of ET-1 (bars in black) observed in both REECs and 
LEECs. 
3.4.1.2 Effect of blockade of the Yj receptor on the NPY-induced increase in 
the extracellular level of ET-1 hREECs and hLEECs 
To investigate the implication of the Y| receptor in the NPY-induced 
increase of the extracellular level of ET-1 at the level of EECs, cultured REECs 
and LEECs were incubated with the Y, receptor antagonist, BIBO3304 (10"6M), 
for 15 minutes before the application of NPY (107M) for 5, 10, 20, 30 and 60 
minutes in the continued presence of the antagonist. Samples of the extracellular 
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media of REECs and LEECs were then collected at each time interval to determine 
the extracellular concentration of ET-1. 
At the level of hREECs, it can be observed from Figure 24A that the 
administration of NPY in the presence of the Yi receptor antagonist, BIBO3304, 
results in a significant rise in the extracellular concentration of ET-1 starting at 20 
minutes after the application of NPY (control value is 4.50 pg/ml + 0.629; 20 
minute value is 9.877 pg/ml ± 1.855; 30 minute value is 11.923 pg/ml ±2.144 and 
the 60 minute value is 13.818 pg/ml + 2.194). 
The effect of NPY in the presence of BIBO3304 was compared to the 
effect of NPY alone (10 7M) and the result is shown in Figure 24B. Panel B shows 
that for each time interval (except at 20 minutes), there is no statistical significance 
between the 2 curves. Panel C of Figure 24 summarizes, in the form of a 
histogram, the time-course effect of NPY alone versus that of BIBO3304 + NPY. 
It can be observed from panel C that NPY in the presence of the Yi receptor 
antagonist was not able to prevent the increase in the extracellular level of ET-1 
induced by NPY (10"7M) alone at the level of REECs (control value is 4.50 pg/ml 
± 0.629; 60 minute value NPY alone is 17.612 pg/ml ± 3.226; 60 minute value 
BIBO3304 + NPY is 13.818 pg/ml ± 2.194). 
At the level of LEECs, Figure 25A shows a significant increase in the 
extracellular concentration of ET-1 starting at 10 minutes following the application 
of NPY(10~7M) in the presence of the Y, receptor antagonist, BIBO3304 (10~6M) 
(control value is 3.612 pg/ml ± 0.444; 10 minute value is 6.408 pg/ml ± 0.613; 20 
minute value is 7.175 pg/ml + 1.122; 30 minute value is 8.795 pg/ml + 1.771 and 
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the 60 minute value is 11.838 pg/ml ± 2.317). In panel B of Figure 25, it can be 
seen that at all the different time intervals tested, there is no significant difference 
between the effect of NPY alone as compared to that of NPY in the presence of 
BIBO3304 (refer to section 3.3 for more details on the effect of NPY alone in 
LEECs). Similar to REECs, panel C shows that the administration of NPY in the 
presence of the Yi receptor antagonist was not able to prevent the NPY-induced 
increase in the extracellular level of ET-1 observed at the level of LEECs after 60 
minutes of treatment (control value is 3.612 pg/ml + 0.444; 60 minute value NPY 
alone is 15.022 pg/ml + 3.032; 60 minute value BIBO3304 + NPY is 11.838 pg/ml 
±2.317). 
3.4.2 Effect of blockade of the Y2 receptor on the NPY-induced secretion of 
ET-1 in hREECs and hLEECs 
In addition to demonstrating the presence of NPY and its Yi receptor in 
hEECs, our group has showed recently that the Y2 receptor is also found at the 
level of both the right and left ventricular hEECs (PERREAULT, 2004). The 
highly selective and non-peptidicYi receptor antagonist, BIIE0246 (DOODS et al, 
1999; DUMONT et al, 2000b; DUMONT et al., 2000c), was used in this series of 
experiments to examine the contribution of the Y2 receptor to the NPY-induced 
secretion of ET-1 in hREECs and hLEECs. 
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3.4.2.1 Effect of blockade of the Y2 receptor on the NPY-induced decrease of 
ET-1 fluorescence intensity in hREECs and hLEECs 
As we saw in section 3.4.1.1, blockade of the Yi receptor was not able to 
prevent the NPY-induced decrease of ET-1 fluorescence intensity in either 
hREECs or hLEECs. For this reason, we sought to investigate the implication of 
the Y2 receptor in such an NPY-induced effect. To do so, cultured hREECs and 
hLEECs were incubated with the Y2 receptor antagonist, BIIE0246 (10"6M), for 15 
minutes followed by the administration of NPY (10~7M) for 5, 10, 20, 30 and 60 
minutes. A control sample, where hREECs and hLEECs were incubated with the 
Y2 receptor antagonist alone for 15 minutes was always performed. It should be 
mentioned that a concentration of 10" M of BIIE0246 is known to completely 
block the Y2 receptor (DOODS et al, 1999; DUMONT et al., 2000b; DUMONT et 
al, 2000c). 
Figure 26 shows an example of a hREEC in control condition (panels a, b 
and c) and following 60 minutes of its exposure to NPY in the presence of 
BIIE0246 (panels d, e and f). In contrast to what was observed with the Yj 
receptor antagonist at the level of hREECs, there seems to be no change in the 
intensity of fluorescence of ET-1 after 60 minutes of NPY application in the 
presence of the Y2 receptor antagonist. On the other hand, the same treatment of 
BIIE0246 (10~6M) + NPY (10~7M) administered for 60 minutes to hLEECs (Figure 
27) had a completely opposite effect, for we can still observe from panels d, e and 
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f that there is a remarkable decrease in the ET-1 fluorescence intensity after 60 
minutes of exposing these cells to NPY in the presence of BIIE0246. 
Measurements of the relative density (by um ) of ET-1 in hREECs and 
hLEECs were taken in the absence and presence of BIIE0246 (10 6M) + NPY (10" 
7M) and these values were compared to those obtained before using NPY alone at 
10"5M (section 3.2.1.4 for hREECs and 3.2.2.4 for hLEECs). Figure 28A shows 
that at the level of hREECs, there is no significant change in the relative density of 
ET-1 after 5, 10, 20, 30 or 60 minutes of exposing these cells to NPY in the 
presence of BIIE0246 when compared to its respective control (bars in red). It can 
be noticed, however, that NPY alone induces a significant decrease in the 
intracellular level of ET-1 starting at 20 minutes of its application to hREECs (bars 
in black). Moreover, at all the time intervals tested (5-60 minutes) in Figure 28A, 
there is a significant statistical difference between the effect of BIIE0246 + NPY 
compared to that of NPY alone. In contrast to hREECs, panel B of Figure 28 
shows that the decrease in the level of ET-1 fluorescence intensity starts to become 
significant after 10 minutes of hLEEC treatment with NPY in the presence of 
BIIE0246 and continues until 60 minutes of this treatment when compared to its 
respective control (bars in red) (control value is 6.618 ± 0.155, n = 42; 10 minute 
value is 6.045 ± 0.179, n = 36; 20 minute value is 6.174 + 0.142, n = 35; 30 minute 
value is 5.965 + 0.145, n = 40 and the 60 minute value is 5.878 ± 0.121, n = 50). 
Blockade, therefore, of the Y2 receptor prevented the NPY-induced decrease of the 
ET-1 fluorescence intensity at the level of hREECs, but not hLEECs. 
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3.4.2.2 Effect of blockade of the Y2 receptor on the NPY-induced increase in the 
extracellular level of ET-1 in hREECs and hLEECs 
As a continuation of the experiments with the Y2 receptor antagonist, BIIE0246, 
and with the aim of confirming the results obtained above in right and left hEECs with 
indirect immunofluorescence and 3-D confocal microscopy, ELISA was used for the 
determination of the extracellular concentration of ET-1 after treatment of hREECs and 
hLEECs with NPY (10"7M) in the presence of BIIE0246 (10"6M) for 5, 10, 20, 30 and 60 
minutes. 
The results presented in Figure 29A show that, at the level of hREECs, there was 
no significant change in the extracellular level of ET-1 following 5, 10, 20, 30 or 60 
minutes of cell exposure to NPY in the continued presence of BIIE0246 when compared 
to the control level. In panel B of Figure 29, the effect of BIIE0246 (10"6M) + NPY (10" 
7M) on the [ET-1 ]0 in hREECs is compared to that of NPY (10"7M) alone. This graph 
shows that there is a statistically-significant difference between the 2 curves at the 60 
minute time interval (p < 0.05). In order to better visualize this difference, we can look 
at the histogram in panel C of the same figure which clearly shows how the Y2 receptor 
antagonist, BIIE0246, was able to prevent the 60-minute NPY- induced rise in the 
extracellular level of ET-1 in right ventricular hEECs (control level is 4.50 pg/ml ± 
0.717; 60 minute level NPY alone 17.612 pg/ml ± 3.226; 60 minute value BIIE0246 + 
NPY is 7.023 pg/ml ± 0.766). 
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For the effect of Y2 receptor blockade in hLEECs, it can be observed from 
Figure 30A that there is a significant rise in the extracellular concentration of ET-1 
starting at 5 minutes of hLEEC exposure to NPY (10~7M) in the presence of 
BIIE0246 (10" M) and continuing to 60 minutes of this exposure (control level is 
3.612 pg/ml + 0.634 and the 5 minute level is 6.529 pg/ml ± 0.540). When the 
effect of BIIE0246 + NPY at the level of hLEECs was compared to that of NPY 
alone (Figure 30B), it was observed that there is no statistically-significant 
difference between the 2 curves at all the times intervals tested. Similar to what 
panel B shows, it can be clearly seen from panel C of Figure 30 that Y2 receptor 
blockade did not prevent the 60-minute NPY-induced rise in the extracellular 
concentration of ET-1 at the level of hLEECs (control level is 3.612 pg/ml + 
0.634; 60 minute level NPY alone 15.021 pg/ml ± 3.032; 60 minute level 
BIIE0246 + NPY is 13.517 pg/ml ± 0.820). 
3.4.3 Effect of double blockade of the Yj and Y2 receptors on the NPY-
induced secretion of ET-1 in hREECs and hLEECs 
In this series of experiments, the Yj receptor antagonist, BIBO3304, and the Y2 
receptor antagonist, BIIE0246, are applied together to hEECs with the purpose of 
examining if their combined administration has a different effect than each 
antagonist used alone. It is worth mentioning that this has been previously reported 
with Yi and Y5 antagonists, where double blockade of the Yi and Y5 receptors had 
a different result on NPY's mitogenic action in VSMCs as compared to each 
antagonist being used alone (ZUKOWSKA-GROJEC et ai, 1998a). 
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3.4.3.1 Effect of double blockade of the Yi and Y2 receptors on the NPY-
induced decrease of ET-1 fluorescence intensity in hREECs and hLEECs 
To investigate the effect of the combined block of the Yiand Y2 receptors 
on the NPY-induced decrease of ET-1 fluorescence intensity, cultured hREECs 
and hLEECs were pre-exposed for 15 minutes to both the Yi receptor antagonist, 
BIBO3304 (10~6M), and the Y2 receptor antagonist, BIIE0246 (1CT6M), at the same 
time. Following the 15-minute pretreatment period, NPY (10"7M) was applied to 
hREECs and hLEECs for time intervals of 5, 10, 20, 30 and 60 minutes. A control 
sample where hREECs and hLEECs were incubated with both antagonists for 15 
minutes without the addition of NPY was always performed. 
Using the technique of indirect immunofluorescence coupled to 3-D 
confocal microscopy, it can be observed from Figure 31 that there is no 
remarkable change in the intensity of ET-1 labeling in hREECs, when comparing a 
cell after 60 minutes of exposure to NPY (10"7M) in the combined presence of 
BIBO3304 (10"6M) + BIIE0246 (10"6M) (panels d, e and f) to another under 
control conditions (panels a, b and c). Similarly, the combined application of both 
Y] and Y2 receptor antagonists (each at a concentration of 10"6M) followed by 
NPY (10~7M) for 60 minutes seems to reverse the NPY-induced decrease in the 
fluorescence intensity of ET-1 (observed earlier in section 3.2.2.3) at the level of 
hLEECs (Figure 32). 
Assessments of ET-1 fluorescence intensities (by unr) in hREECs and 
hLEECs, treated with NPY (10~7M) in the presence of both BIBO3304 and 
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5 
BIIE0246 (each at 10~6M), were taken, and the values obtained here were 
compared to those obtained before using NPY alone at 10"5M. At the level of 
hREECs, it can be observed from Figure 33A, that there is no significant change in 
the relative density of ET-1 after 5, 10, 20, 30 or 60 minutes of cell exposure to 
BIBO3304 + BIIE0246 + NPY as compared to its respective control. In addition, 
when the effect of NPY in the presence of both the Yi and Y2 receptor antagonists 
(bars in red) is compared to that of NPY alone (bars in black) at all the different 
time intervals tested, it can be observed that there is a statistically-significant 
difference between the 2 curves starting at 10 minutes and continuing until 60 
minutes of treatment. 
Similar to hREECs, there is no significant change in the relative density of 
ET-1 in hLEECs (Figure 33B) after 5, 10, 20, 30 or 60 minutes of cell exposure to 
NPY in the presence of BIBO3304 + BIIE0246 as compared to its respective 
control. Moreover, there is a statistically-significant difference (p < 0.05) between 
the 60-minute effect of NPY in the presence of BIBO3304 + BITE0246 (bars in 
red) as compared to that of NPY alone (bars in black). 
As a conclusion of this series of experiments, double blockade of the Yi 
and Y2 receptors seems to reverse the NPY-induced decrease of ET-1 fluorescence 
intensity. 
3.4.3.2 Effect of double blockade of the Yi and Y2 receptors on the NPY-
induced increase in the extracellular level of ET-1 in hREECs and hLEECs 
The results obtained for the double blockade of the Yi and Y2 receptors, 
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using indirect immunofluorescence and 3-D confocal microscopy, were both 
interesting and surprising, especially since they were different at the level of 
hLEECs from those obtained when either the Yi or the Y2 receptor was blocked. 
To confirm these results, ELISA was used to determine the extracellular level of 
ET-1 in the culture medium of hREECs and hLEECs treated with NPY (10'7M) in 
the presence of both BIBO3304 (10"6M) and BIIE0246 (10"6M) for 5, 10, 20, 30 
and 60 minutes. It should be mentioned that similar to all the experiments done 
before, hREECs and hLEECs were exposed to both the Yi and Y2 receptor 
antagonists for 15 minutes before the application of NPY, and that control samples 
where hEECs were exposed to both antagonists at the same time for 15 minutes 
without the further administration of NPY were also done. 
Figure 34A shows the ELISA results obtained at the level of hREECs in 
the absence (time 0) and presence of BIBO3304 + BIIE0246 + NPY for 5, 10, 20, 
30 and 60 minutes. It can be clearly observed from panel A that there is no 
significant increase in the extracellular concentration of ET-1 at all the time 
periods tested as compared to the control level. When the effect of NPY (10"7M) in 
the presence of both the Y] and Y2 receptor antagonists each at a concentration of 
10"6M (Figure 34B; curve in red) is compared to that of NPY alone (10"7M) (curve 
in black) at all the different time intervals tested, it can be observed that there is a 
statistically-significant difference (p < 0.05) between the 2 curves at the 60-minute 
time interval. This latter (i.e. the 60-minute effect) is summarized in panel C of the 
same figure, where it can be observed that the extracellular level of ET-1 in 
hREECs that have been treated with BIBO3304 + BIIE0246 + NPY for 60 minutes 
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is almost the same as the control level (control level is 4.50 pg/ml ± 0.916; 60 
minute level BIBO3304 + BIIE0246 + NPY is 7.838 pg/ml ± 1.489 ), whereas it is 
almost 4 fold higher in hREECs that have been treated with NPY alone for 60 
minutes (17.612 pg/ml ± 3.226). 
At the level of hLEECs, it can be observed from panel A of Figure 35 that 
the application of NPY (10 7M) in the presence of both the Y] and Y2 receptor 
antagonists, each at a concentration of 10"6M, for 5, 10, 20, 30 and 60 minutes 
resulted in no increase in the extracellular concentration of ET-1 when compared 
to the control level. Similar to hREECs, comparison of the effect of NPY alone 
(10~7M) to that of NPY (10~7M) in the presence of BIBO3304 + BIIE0246 (each at 
10"6M) on the extracellular level of ET-1 at the different time periods tested, 
produces a statistically-significant difference (p < 0.05) at the 60-minute time 
interval (Figure 35B). Again, this difference between the effect of NPY alone and 
that of BIBO3304 + BIIE0246 + NPY at 60 minutes of hLEEC treatment with one 
or the other is summarized in panel C of Figure 35. 
The results obtained with ELISA in this section thus confirmed those 
obtained with indirect immunofluorescence and 3-D confocal microscopy in the 
previous section, which seem to suggest that simultaneous blockade of the Yi and 
Y2 receptors is able to reverse the NPY-induced secretion of ET-1 at the level of 
both hREECs and hLEECs. 
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3.4.4 Effect of blockade of the Y5 receptor on the NPY-induced secretion of 
ET-1 in hREECs and hLEECs 
The two main receptors thought to play a major role in peripheral 
cardiovascular control are the Yi and Y2 receptors (UDDMAN et ah, 2002). This, 
however, does not exclude the possibility of involvement of other NPY receptors, 
such as the Ys receptor. Unfortunately, the lack of availability of reliable 
antibodies directed against the Y5 receptor protein prevented us from investigating 
its presence at the level of the endocardial endothelial cells. Fortunately, though, 
due to the recent availability of a potent and highly-selective Y5 receptor 
antagonist, L-l52,804 (KANATANI et al, 2000), we were able to examine the 
participation of the Y5 receptor in the ET-1 secretory effect induced by NPY in 
right and left ventricular hEECs. 
3.4.4.1 Effect of blockade of the Y5 receptor on the NPY-induced decrease of 
ET-1 fluorescence intensity in hREECs and hLEECs 
To investigate the implication of the Ys receptor in the decrease of the 
intensity of ET-1 labeling induced by NPY, cultured hREECs and hLEECs were 
pretreated for 15 minutes with the Y5 receptor antagonist, L-l52,804 (10~6M), 
followed by the extracellular application of NPY (10~7M) for 5, 10, 20, 30 and 60 
minutes. A control sample where hEECs were incubated with the Y5 receptor 
antagonist alone for 15 minutes was also performed. 
- 155 -
Using indirect immunofluorescence followed by examination with the 
confocal microscope to check for any change in the fluorescence intensity of ET-1 
as a result of the above-mentioned treatment, it can be observed from Figure 36 
that there is no remarkable change in the intensity of labeling of ET-1 in hREECs 
that have been exposed to NPY (10~7M) in the presence of L-152,804 (1CT6M) for 
60 minutes (panels d, e and f) as compared to those in control condition (panels a, 
b and c). Figure 37 shows the same result but at the level of hLEECs, where the 
lack of change in the fluorescence intensity of ET-1 is obvious in panels d, e and f 
(60-minute treatment with L-152,804 + NPY) when compared to panels a, b and c 
(cell in control conditions). 
As was previously done, measurements of the relative density of ET-1 (by 
um3) in both hREECs and hLEECs were taken using the 3-D reconstructions of 
cells obtained from the confocal microscopy experiments. These measurements 
were taken under control conditions and following the exposure of hREECs and 
hLEECs to L-152,804 (10~6M) + NPY (10~7M) for 5, 10, 20, 30 and 60 minutes. 
Values obtained were then compared with those obtained earlier when studying 
the effect of NPY alone (10'M) on the level of ET-1 fluorescence intensity 
(section 3.2.1.4 for hREECs and 3.2.2.4 for hLEECs). Looking at Figure 38A, 
which shows the result of the administration of L-152,804 (10"6M) + NPY (10"7M) 
to hREECs for 5, 10, 20, 30 and 60 minutes as compared to that of the 
administration of NPY alone (10"5M) for the same time intervals, it can be seen 
that there is a statistically-significant difference between both treatments (p < 
0.001) starting at the 10-minute time interval and continuing till the 60-minute 
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interval. This suggests that blockade of the Y5 receptor seems to be able to 
counteract the NPY-induced decrease of ET-1 fluorescence intensity observed in 
hREECs. 
At the level of hLEECs (Figure 38B), blockade of the Y5 receptor resulted 
in no significant change in the relative density of ET-1 after 5, 10, 20, 30 or 60 
minutes of application of L-152,804 (10"6M) + NPY (10"7M) as compared to its 
respective control. Meanwhile, NPY alone resulted in a significant decrease of the 
ET-1 relative density observed after 60 minutes of treatment as compared to its 
respective control (control level is 7.013 ± 0.208, n = 30 and the 60 minute level is 
6.423 ± 0.175, n = 33). When the effect of Y5 receptor blockade is compared to 
that of NPY alone, it can be observed from panel B of the same figure that there is 
a statistically-significant difference (p < 0.05) between both treatments after 60 
minutes of their application. 
3.4.4.2 Effect of blockade of the Y5 receptor on the NPY-induced increase in 
the extracellular level of ET-1 in hREECs and hLEECs 
Similar to what was previously done throughout this study, each series of 
experiments conducted using the techniques of indirect immunofluorescence and 
3-D confocal microscopy is always followed by a second series of confirmatory 
experiments performed using the technique of ELISA, where the same treatment is 
done but with the additional step of collecting samples for the determination of the 
extracellular concentration of ET-1. Experiments done with the Ys receptor 
antagonist, LI 52,804, were conducted in the same way. Results of the ELISA 
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experiments for the blockade of the Y5 receptor are presented in Figure 39 and 
Figure 40 corresponding to hREECs and hLEECs, respectively. 
For hREECs, it can be observed from Figure 39A that the application of NPY (10" 
7M) in the presence of the Y5 receptor antagonist, L-152,804 (10"6M), induced a 
significant rise in the extracellular concentration of ET-1 starting at 10 minutes of 
this treatment and attaining a maximum after 60 minutes as compared to the 
control (control level is 4.5 pg/ml ± 0.567; 10 minute level is 7.348 pg/ml ± 1.012; 
20 minute level is 8.108 pg/ml + 1.062; 30 minute level is 8.336 pg/ml + 0.865 and 
the 60 minute level is 10.311 pg/ml + 0.963). When the 2 treatments, namely NPY 
alone versus NPY in the presence of L-152,804, are compared with each other in 
panel B of the same figure, it can be observed that there is a statistically-
significant difference (p < 0.05) between their effects on the extracellular level of 
ET-1 at the 60-minute time interval. Panel C of Figure 39 shows that despite the 
significant difference between the 60-minute effect of NPY (10" M) alone as 
compared to that of L-152,804 (10"6M) + NPY (10"7M), the rise induced by the 
latter in the extracellular concentration of ET-1 is still highly significant when 
compared to the control (control level is 4.5 pg/ml + 0.567; level at 60 minutes L-
152,804 + NPY is 10.309 pg/ml ± 0.963). This suggests the partial implication of 
the Y5 receptor in the NPY-induced secretion ET-1 at the level of hREECs. 
As for hLEECs (Figure 40), panel A shows that there is no significant rise 
in the extracellular concentration of ET-1 upon exposure of these cells to 5, 10, 20, 
30 or 60 minutes of NPY (10"7M) in the presence of 10"6M of the Y5 receptor 
antagonist. Panel B of the same figure shows the comparison between the effect of 
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NPY alone (black curve) versus that of NPY in the presence of L-152,804 (red 
curve) at all the different time intervals tested. It can be observed that there is a 
statistically-significant difference between the 2 treatments seen at the 10-minute 
and the 60 minute intervals (p < 0.01). Panel C summarizes the effect that we 
already saw in panel B at 60 minutes in histogram form, and here it can be clearly 
observed that treatment of hLEECs with L-152,804 (10~6M) + NPY (10"7M) for 60 
minutes was able to completely inhibit the NPY-induced rise in the extracellular 
level of ET-1 (control level is 3.612 pg/ml + 0.416; level at 60 minute NPY alone 
is 15.022 pg/ml ± 3.032; level at 60 minute L-152,804 + NPY is 5.447 pg/ml ± 
0.866). 
3.5 Role of the ET-1 receptors, ETA and ETB, in the NPY-induced 
secretion of ET-1 in hREECs and hLEECs 
So far we have examined the implication of the NPY receptors, Y ] ; Y2 and 
Y.s in the NPY-induced secretion of ET-1 in right and left ventricular hEECs. 
However, among the investigations into control of ET-1 secretion are a limited 
number which suggest its ability to modulate its own production and release 
(SAUONMAA et al, 1992; EVANS et al., 2003). Therefore, in the following two 
series of experiments, we sought to explore this matter by looking into the role of 
the ET-1 receptors, ETA and ETB in the secretion of ET-1 induced by NPY at the 
level of hREECs and hLEECs. In other words, we wanted to examine if the ET-1 
secreted upon hEEC exposure to NPY is further stimulating its own release via the 
activation of its receptors, ETA and ETB. 
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3.5.1 Effect of blockade of the ETA receptor on the NPY-induced secretion 
of ET-1 in hREECs and hLEECs 
To investigate the role of the ETA receptor in the NPY-induced secretion of 
ET-1 in hREECs and hLEECs, we used the non-peptidic ETA receptor selective 
antagonist, ABT-627 (VON GELDERN et a/., 1999; CHIOU et al, 2000; 
WESSALE et al, 2002), to conduct the indirect immunofluorescence, 3-D 
confocal microscopy and ELISA experiments described below. 
3.5.1.1 Effect of blockade of the ETA receptor on the NPY-induced decrease of 
ET-1 fluorescence intensity in hREECs and hLEECs 
In this series of experiments, cultured hREECs and hLEECs were 
pretreated with the ETA receptor antagonist, ABT-627 (10~7M), for 15 minutes 
followed by the application of NPY (10 7M) for 5, 10, 20, 30 and 60 minutes in the 
continued presence of the antagonist. Control samples, where hREECs and 
hLEECs were incubated with ABT-627 (10~7M) for 15 minutes without the further 
application of NPY, were also performed. 
Using indirect immunofluorescence coupled to 3-D confocal microscopy, 
Figure 41 shows a slight, yet noticeable, decrease in the fluorescence intensity of 
ET-1 in hREECs at 60 minutes of cell exposure to NPY (10"7M) in the presence of 
ABT-627 (10~7M) (panels d, e and f) as compared to control conditions (panel a, b 
and c). This decrease in ET-1 fluorescence intensity can be noticed throughout the 
entire cell (cytosol and nucleus) and particularly in the cytosol owing to the 
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observation of more 'low-signal' (dark blue), and even 'absence-of-signal' (black), 
areas in panels d, e and f as compared to a, b and c. However, at the level of 
hLEECs (Figure 42), the decrease in the ET-1 fluorescence intensity at 60 minutes 
of treatment with ABT-627 + NPY (panels d, e and f) is much more remarkable 
and significant when compared to that observed in Figure 41 at the level of 
hREECs. 
Assessments of ET-1 fluorescence intensities (by urn) in hREECS and 
hLEECs were taken in the absence and presence of ABT-627 (10~7M) + NPY (10" 
7M) for 5, 10, 20, 30 and 60 minutes. These measurements were done using the 3-
D reconstructions of hEECs obtained from the confocal microscopy experiments. 
The values obtained here were compared to those obtained earlier when studying 
the effect of NPY alone (10~5M) on the fluorescence intensity of ET-1 (section 
3.2.1.4 for hREECs and 3.2.2.4 for hLEECs). At the level of hREECs, Figure 43A 
shows that the application of NPY (10~7M) in the presence of ABT-627 (10"7M) 
resulted in a significant decrease in the level of ET-1 fluorescence intensity 
starting at 20 minutes of the aforementioned treatment to attain a maximum after 
60 minutes (control level is 9.388 ± 0.183, n = 32; 20 minute level is 8.237 ± 
0.207, n = 46; 30 minute level is 8.045 ± 0.207, n = 59 and the 60 minute level is 
7.266 ± 0.212, n = 57). Similarly, the application of NPY alone (10"5M) also 
resulted in a significant decrease in the ET-1 relative density starting at 20 minutes 
and continuing till 60 minutes of hREEC exposure to NPY as compared to its 
respective control. However, when the effect of ABT-627 + NPY is compared to 
that of NPY alone, it can be observed that despite the significant decrease in the 
-173-

ETA ant + NPY 
60 min Control 

[E
T-1
]j F
lu
or
es
ce
nc
e 
In
te
ns
ity
 
(by
 
p.m
3 ) 
CO
 
[E
T-1
]j F
lu
or
es
ce
nc
e 
In
te
ns
ity
 
(by
 ^
im
3 ) 
o
 
o
 I 
en
 
i 
3 
-
3 
II 
II 
CO
 
CO
 
fO
 
CO
 
OJ
 
CO
 
o
 
.
 »
 05
 
O
 
|M
 
»
^
.
*
 
_
 
*
 
II m z 3. ii + w z "0 -< 
o
 U
l 
r- m
 
m
 
O
 
<0
 
H i 1 3 
_
i 0 r\3
 
0 30 60 
33
 
m
 
m
 
O
 
CO
 
level of ET-1 fluorescence intensity induced by the former treatment, there is a 
statistically-significant difference between both treatments starting at the 10-
minute time interval and continuing till the 60-minute interval. These results 
suggest the partial implication of the ETA receptor in the NPY-induced decrease of 
ET-1 labeling intensity in hREECs. Panel B of Figure 43 shows the change in the 
[ET-l]j fluorescence intensity in hLEECs as a function of time following the 
administration of NPY (10"7M) in the presence of ABT-627 (10~7M) as well as at 
the level of the control. Similar to what was observed in hREECs, there is a 
significant decrease in the level of ET-1 fluorescence intensity starting at 20 
minutes of ABT-627 + NPY application and continuing till 60 minutes as 
compared to its respective control (ET-1 relative density at control level and after 
20, 30 and 60 minutes of ABT-627 + NPY application are respectively as follows: 
7.168 ± 0.178, n = 26; 6.434 ± 0.2501, n = 19; 6.554 ± 0.255, n = 19 and 6.133 ± 
0.167, n = 23). However, and in contrast to hREECs, there is no statistical 
significance between the effect of the ETA receptor antagonist + NPY (bars in red) 
treatment when compared to that of NPY alone (bars in black).This suggests that 
blockade of the ETA receptor was not able to reverse the decrease in the 
fluorescence intensity of ET-1 induced by NPY at the level of hLEECs. 
3.5.1.2 Effect of blockade of the ETA receptor on the NPY-induced increase in 
the extracellular level of ET-1 in hREECs and hLEECs 
To confirm the results obtained with the ETA receptor antagonist, ABT-
627, using indirect immunofluorescence and 3-D confocal microscopy, EL1SA 
-178-
was used again in this series of experiments with the purpose of examining the 
change in the extracellular concentration of ET-1, after subjecting cultured 
hREECs and hLEECs to NPY (10"7M) in the presence of 10"7M of ABT-627 for 
the different time intervals used in all of the previously done experiments. Figure 
44A shows the increase in the [ET-1]0 at the level of hREECs that have been 
exposed to the above-mentioned treatment, an increase which becomes 
statistically-significant (p < 0.05) after 60 minutes of such a treatment ([ET-1 ]0 in 
pg/ml at time 0 and after 60 minutes of hREEC exposure to ABT-627 + NPY is, 
respectively, as follows: 4.49 ± 0.768 and 9.734 ± 1.369). Despite the above-
mentioned increase in the extracellular level of ET-1 observed after 60 minutes of 
ABT-627 + NPY application to hREECs, there is a statistically-significant 
difference (p < 0.05) between the 2 curves (i.e. that of NPY alone versus ABT-627 
+ NPY) at the 60-minute time interval (Figure 44B). This 60-minute-effect of 
NPY alone (10"7M) versus that of NPY (107M) in the presence of ABT-627 (10" 
7M) is best illustrated in panel C of Figure 44. These ELISA results, thus, confirm 
those of indirect immunofluorescence which suggest the partial implication of the 
ETA receptor in the NPY-induced secretion of ET-1 in hREECs. 
At the level of hLEECs, the administration of NPY (10"7M) in the presence 
of the ETA receptor antagonist (10"7M) induces a significant rise in the 
extracellular level of ET-1 after 60 minutes of its application as compared to the 
control (Figure 45A), and this is similar to what we observed with the same 
antagonist at the level of hREECs. However, in contrast to hREECs, there is no 
statistical significance between the effect of the NPY (10"7M) treatment as 
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compared to that of the ABT-627 (10"7M) + NPY (10"7M) treatment at all the time 
intervals tested (Figure 45B). Panel C provides a summary, in histogram form, of 
the 60-minute effect of both treatments mentioned above on the extracellular 
concentration of ET-1, where we can observe the statistical significance (p < 0.01) 
of the similar ET-1 rise as a result of both treatments as compared to the control 
(control ET-1 3.612 pg/ml + 0.838; ET-1 at 60 minutes NPY alone 15.0218 pg/ml 
± 3.032; ET-1 at 60 minutes ABT-627 + NPY 12.795 pg/ml + 2.570). 
3.5.2 Effect of blockade of the ETB receptor on the NPY-induced secretion 
of ET-1 in hREECs and hLEECs 
Results of the previous section showed that the ETA receptor does not seem to be 
implicated in the NPY-induced ET-1 secretion at the level of hLEECs; or more 
accurately, the ET-1 secreted as a result of hLEEC stimulation by NPY does not 
seem to be further mediating its own release via activation of the ETA receptor. 
However, the latter receptor seems to be partially implicated in this ET-1 
mediated-ET-1 release at the level of hREECs. To examine the role of the ETB 
receptor in this matter, we used the non-peptidic ETB receptor selective antagonist, 
A192621 (VON GELDERN et ai, 1999; WESSALE et al, 2002) in the indirect 
immunofluorescence, 3-D confocal microscopy and ELISA experiments described 
below. 
- 182-

o
 
m
 
ET
-1
(pg
/m
l) 
ET
-1
(pg
/m
l) 
ET
-1
(pg
/m
l) 
o
 
o
 
o
 
z 
z 
if 
II 
l 
I a 3 
M
 
O
 
3 
O
 
o
 
01
 
o
 
(3
5 o
 
-
J o
 
o
 
IN
3 o
 
o
 
t-
tf~
i 
II CO
 
\ 
m
 
o
 At
 
as
 
3 at <Q
 
+
 Z TJ
 
•<
 
O
 s 
3.5.2.1 Effect of blockade of the ETB receptor on the NPY-induced decrease of 
ET-1 fluorescence intensity in hREECs and hLEECs 
In this series of experiments, and similar to what was done throughout this 
study, indirect immunofluorescence and 3-D confocal microscopy were used on 
hREECs and hLEECs that were exposed, as a first step, to the ETB receptor 
antagonist, A192621 (10" M) for 15 minutes. Following this 15-minute incubation 
period, hREECs and hLEECs were subjected to NPY (10"7M) in the continued 
presence of the antagonist for 5, 10, 20, 30 and 60 minutes. Control samples of 
both right and left hEECs, where cells were exposed to 15 minutes of the ETB 
receptor antagonist alone without the further addition of NPY, were also done in 
parallel to the test samples. 
Figure 46 shows, in panels a, b and c, a hREEC under control conditions, 
and in panels d, e and f, another after 60 minutes of exposure to NPY in the 
presence of A192621. It can be clearly observed from this figure that there is no 
remarkable change in the intensity of labeling of ET-1 in hREECs between the 2 
time intervals displayed. On the other hand, if we look at the effect of the same 
treatment (10"7M of A192621 + 10~7M of NPY) at the level of hLEECs (Figure 
47), we can observe that there is a remarkable decrease in the ET-1 fluorescence 
intensity at 60 minutes of its administration (d, e and f) as compared to the control 
(a, b and c). This decrease is seen throughout the entire cell, and it is especially 
noticeable at the cytosolic level. 
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Measurements of the ET-1 relative density (by urn3) in both hREECs 
(Figure 48A) and hLEECs (Figure 48B) were taken using the 3-D reconstructions 
of cells obtained through the confocal microscopy experiments. These 
measurements were done under control conditions, and following 5, 10, 20, 30 and 
60 minutes of hREEC and hLEEC exposure to 107M of A192621 + 10"7M of 
NPY. As was always done before, these measurements were made for the purpose 
of comparing the effect of hEEC stimulation with NPY alone versus that of NPY 
in the presence of ETB receptor antagonist. At the level of hREECs, panel A of 
Figure 48 shows that there is no significant change in the relative density of ET-1 
after 5, 10, 20, 30 or 60 minutes of hREEC exposure to NPY (10"7M) in the 
-7 
presence of A192621 (10~ M) as compared to its respective control. It should be 
mentioned that NPY on its own (black bars) induced a remarkable decrease in 
LET-lJj fluorescence intensity, one which became statistically-significant after 20 
minutes of hREEC exposure to NPY. Moreover, when the effects of both 
treatments (i.e. ETB receptor antagonist + NPY versus NPY alone) were compared 
at all the different time intervals tested, it could be clearly seen that there is a 
statistically-significant difference between the 2 histograms starting at the 5-
minute time interval and maintained through the 60-minute time interval. In 
contrast to hREECs, it can be observed from panel B of the same figure that the 
decrease in the level of ET-1 fluorescence intensity as a result of hLEEC treatment 
with NPY (10"7M) in the presence of A192621 (10"7M) starts to become significant 
after only 5 minutes of such a treatment, and reaches a maximum after 60 minutes 
as compared to its respective control (control, 5, 10, 20, 30 and 60 minutes [ET-1]; 
fluorescence intensity levels are, respectively, as follows: 7.189 + 0.146, n = 23; 
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6.606 ± 0.170, n = 23; 6.245 ± 0.106, n = 25; 6.067 + 0.174, n = 23; 5.892 ± 0.125, 
n = 23 and 5.486 + 0.126, n = 29). 
3.5.2.2 Effect of blockade of the ETB receptor on the NPY-induced increase in 
the extracellular level of ET-1 in hREECs and hLEECs 
To confirm the results of the indirect immunofluorescence and 3-D 
confocal microscopy experiments obtained in section 3.5.2.1, we conducted a 
series of experiments using ELISA, after having treated cultured hREECs and 
hLEECs with NPY (10"7M) in the presence of the ETB receptor antagonist, 
A192621 (10~7M) for 5, 10, 20, 30 and 60 minutes. As always, hEECs were 
pretreated with A192621, at the same concentration mentioned in section 3.5.2.1, 
for 15 minutes to ensure the complete block of the ETB receptor before the 
application of NPY. Control samples of both hREECs and hLEECs were also done 
by incubating these cells with the antagonist on its own for 15 minutes without 
being followed by the administration of NPY. The results of these experiments are 
presented in Figure 49 and Figure 50 corresponding to hREECs and hLEECs, 
respectively. 
At the level of hREECs, Fi gure 49A shows that there is a minor rise in the 
extracellular concentration of ET-1 as a function of time following hREEC 
exposure to NPY (10"7M) in the presence of A192621 (10~7M). This rise however 
is insufficient to be statistically significant when compared to control level at any 
of the time intervals tested. More importantly, when the effect of NPY alone on 
the extracellular level of ET-1 is compared to that of A192621 + NPY in panel B 
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of the same figure, it can be clearly observed that there is a statistical significance 
(p < 0.05) between both effects at 60 minutes of applying either the former or the 
latter treatment. This is well-summarized in histogram form in panel C, where we 
can observe that blockade of the ETB receptor was able to abolish the 60-minute 
NPY-induced rise in the extracellular concentration of ET-1 at the level of 
hREECs (control level: 4.49 pg/ml ± 0.742; 60 minutes NPY alone: 17.612 pg/ml 
± 3.226; 60 minutes A192621 + NPY: 7.87 pg/ml + 1.653). 
On the other hand, at the level of hLEECs (Figure 50A), administration of 
NPY at 10~7M in the presence of Al92621 at the same concentration induces a 
significant increase in the [ET-1 J0 after 60 minutes of its application (p < 0.05), as 
compared to the control level. In contrast to what was observed in hREECs upon 
blockade of the ETB receptor, panel B of Figure 50 shows that there is no 
statistically-significant difference between the 2 curves produced as a result of 
hLEEC treatment with NPY alone versus their treatment with NPY in the presence 
of Al92621. This absence of significance is observed at all the time intervals 
tested. In panel C, we can observe that the ETB receptor antagonist + NPY, applied 
for 60 minutes to hLEECs, induces a similar rise in the extracellular concentration 
of ET-1 as that induced by NPY on its own (control level: 3.611 pg/ml ± 1.059; 60 
minutes NPY alone: 15.022 pg/ml + 3.032; 60 minutes A192621 + NPY: 13.319 
pg/ml ± 3.622). 
As a conclusion for the studies conducted using the ETB receptor 
antagonist, it can be suggested that, at the level of hREECs, but not hLEECs, ETB 
receptor blockade was able to reverse the NPY-induced secretion of ET-1. 
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IV. DISCUSSION 
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4.1 Use of confocal microscopy to study secretion 
The hypothesis proposed for this study, and as mentioned in section 1.5 of 
the chapter 'Introduction', is that a dialogue between the system of NPY and that 
of ET-1 exists at the level of right and left ventricular EECs isolated from 20-
week-old human fetal hearts. This hypothesis was laid forth because of the 
compiled evidence obtained from our lab such as: 1) the presence of NPY and its 
receptors, Yi and Y2, as well as ET-1 and its receptors ETA and ETB in EECs, 2) 
the ability of both peptides to induce a calcium rise after activation of their 
receptors in these cells, 3) secretion of NPY by EECs and 4) the asymmetry 
observed between REECs and LEECs. Furthermore, this hypothesis is also 
supported by the literature relating to the secretion of various cardioactive factors, 
including ET-1, by EECs and the crosstalk that exists between ET-1 and a variety 
of these mediators at the level of the cardiovascular system. 
As a first objective in examining the existence of such a dialogue between 
NPY and ET-1, we proceeded to test if NPY, at concentrations varying from very 
low (10"15M) to very high (10"5M), is able to induce the secretion of ET-1 from 
right and left ventricular EECs. This secretory effect was examined using, first, the 
technique of indirect immunofluorescence coupled to 3-D confocal microscopy, 
followed by the technique of ELISA. Using the former technique, there was a 
dose-dependent decrease in the relative density of ET-1 after exposure of EECs to 
NPY, an effect which suggested secretion. To confirm whether such a decrease 
was indeed secretion, we used a more classical method, ELISA. The results using 
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this technique revealed that the decrease in the intracellular relative density of ET-
1 was paralleled by an increase in the extracellular level of this peptide. One might 
argue at this point about how reliable it is to talk of relative density when actually 
we are measuring fluorescence intensity. In fact, one of the major elements in 
confocal microscopy is the setting and maintaining of the optimal parameter 
conditions for a given fluorescent probe. In order to optimize and validate our 
fluorescence intensity measurements, all our settings on the confocal microscope 
were kept constant throughout the experimental procedures. These settings 
include: pinhole or aperture size, pixel size, step size, laser line intensity, 
photometric gain, photomultiplier tube (PMT) settings and filter attenuation which 
ensures that there will be no photobleaching (BKAILY et al, 1997; BKAILY et 
al, 1999). Not only were the settings on the microscope kept constant, but the 
concentration of both the primary (directed against ET-1) and secondary 
antibodies were also maintained throughout the study, and the fluorescence 
intensity measurements were performed over the entire cell volume, and not in one 
or a few sections, to provide realistic 3-D information (BKAILY et al, 2003b). 
Therefore, the confocal microscopy technique is an excellent and accurate tool to 
study secretion. Moreover, since our results using ELISA confirmed that the 
decrease in intracellular ET-1, which was observed using immunofluorescence, is 
due to ET-1 secretion, then it can be said that both techniques are indeed 
complementary. 
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4.2 Nuclear buffering of cytosolic calcium could explain the different 
kinetics of ET-1 secretion at NPY 10 1 5 , 10 1 ( ) and 10 5M in both hREECs 
and hLEECs 
As mentioned above, we proceeded in this study, as a first objective, with 
testing the effect of varying concentrations of NPY (1(T13M - 10"5M) on the 
secretion of ET-1 from right and then left ventricular human EECs. Our results at 
the level of REECs showed that 10 13M and 10~3M of NPY induced the secretion 
of ET-1 in a time-dependent fashion. However, 10"10M of NPY induced the 
secretion of ET-1 only after 60 minutes of treatment. In 2003, Bkaily et al. 
showed, using the sarcolemma membrane perforation technique in heart and 
human aortic VSMCs, that increasing the cytosolic calcium concentration 
gradually from 100 nM (control) to 2000 nM, we can observe a rise in nuclear 
calcium (nuclear buffering of cytosolic calcium) starting from an extranuclear 
calcium concentration of 200 nM. The nuclear calcium keeps increasing in a dose-
dependent fashion until the extranuclear calcium reaches a concentration of 1200 
nM. Further elevation of the latter to 1600 and even 2000 nM did not cause a 
further rise in nuclear calcium (BKAILY et al, 2003a). This suggests that nuclear 
buffering of cytosolic calcium starts at a given threshold concentration of 
extranuclear calcium and stops at another given concentration beyond which it 
cannot continue to buffer any more cytosolic calcium. The above-mentioned 
results can probably explain the dose and time-dependent secretion of ET-1 
induced by 10"15, 10~10 and 10 5M of NPY in REECs. In other words, this suggests 
that upon the application of NPY (10"15M) to REECs, there is an increase in the 
cytosolic calcium. However, this increase is probably not sufficient to reach the 
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threshold at which the nucleus starts buffering the rise in the cytosolic calcium 
level. Calcium, therefore, rapidly accumulates in the cytosol causing this early 
secretory response that was observed in REECs with NPY (10"bM). On the other 
hand, upon application of 10"10M of NPY to REECs, we suggest that the resulting 
rise in the cytosolic calcium level is enough to reach the threshold of the nuclear 
buffering capacity. As a result of calcium being taken in by the nucleus, we can 
only observe secretion of ET-1 at 60 minutes of treatment with NPY (10~10M) 
when the accumulated calcium in the cytosol is enough to elicit a secretory 
response. At the highest NPY concentration used (10~M), we suggest that the 
nucleus reaches the limit for its buffering capacity of the rise in cytosolic calcium, 
thus allowing the latter to accumulate again and elicit ET-1 secretion from REECs 
as early as 20 minutes after treatment with 10"5M of NPY. The same concept 
discussed above can be used to explain the results obtained in LEECs, where 
secretion of ET-1 is observed at 60 minutes of treatment with NPY at 10"l5and 10" 
5M of NPY, but not at all using NPY (10"'°M) where buffering of the nucleus for 
the rise in cytosolic calcium does not allow for calcium accumulation and 
therefore ET-1 secretion. However, if the same concept of nuclear buffering 
applies to REECs and LEECs, the question that could be asked here is why we 
observe ET-1 secretion in LEECs only at 60 minutes of application of NPY at 10" 
' M and 10"'M and not as early as that observed in REECs. Recent results obtained 
by our group showing the effect of increasing concentrations of NPY (10" ", 10"1 , 
10"7 and 10"5M) on the LCa]c and LCaJn in human REECs and LEECs showed that 
under control conditions, the basal level of [Ca]c and [Ca]n in REECs is lower than 
that in LEECs (SADER, 2002). This suggests that in REECs, and upon agonist 
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stimulation, it will take more time for the rising cytosolic calcium to reach the 
minimum threshold at which the nucleus starts its buffering activity. Therefore, 
calcium has the chance to accumulate in the cytosol and elicit an early ET-1 
secretory response. On the other hand, since the basal calcium level is higher in 
LEECs than in REECs, any change in the LCa]c will bring the latter to the 
minimum threshold required for the nucleus to start its buffering activity. Indeed, 
the above-mentioned results obtained recently by our group showed that at 1CT15M 
of NPY, the rise in [CaJn observed in LEECs is higher than that observed in 
REECs, suggesting more nuclear buffering of cytosolic calcium in the former type 
of cells than in the latter at NPY (10"15M) (SADER, 2002). Since any flux or rise 
in the intracellular calcium level of LEECs at NPY (10"15M) is going to be 
buffered immediately by the nucleus, this suggests that it would take longer for the 
cytosolic calcium to accumulate enough to induce the secretion of ET-1. This 
could possibly explain the secretion of ET-1 observed only at 60 minutes of LEEC 
treatment with 10 15M of NPY. But what about the total lack of an NPY effect in 
LEECs after treatment with NPY (10~ M) and a secretory effect observed only at 
60 minutes after application of 10" M of NPY to the same type of cells? In 
addition to the concept of nuclear buffering described earlier, a possible 
explanation for these results could be a higher capacity of ET-1 synthesis in 
LEECs as compared to REECs which masks any decrease in the intracellular 
density of ET-1 that could have otherwise been detected. In accordance with these 
results, our group has recently demonstrated, using 20-week-old human REECs, 
that stimulation of these cells with a sustained depolarization of the cell membrane 
(caused by 30 mM of extracellular KC1) induced a sustained rise in the [Ca]c and 
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[Caln (JACQUES et al, 2000a; JACQUES et al, 2003b) that resulted in the 
secretion of NPY from these cells (SADER, 2002; JACQUES et al, 2003b; 
ABDEL-SAMAD et al, 2007) in a time-dependent manner. In contrast, the same 
treatment with KC1 at 30 raM did not elicit the release of NPY from human 
LEECs, but rather resulted in an increase in the intracellular concentration of this 
peptide. This suggested that a sustained rise in the [Ca]i caused by a sustained 
depolarization of the membrane leads to de novo synthesis of NPY in EECs 
isolated from the left, but not the right, ventricle. Similarly, the lower secretory 
capacity of LEECs as compared to REECs observed in this study with NPY (10 10 
and 10 M) could indicate that the NPY-induced release of ET-1 in these cells is 
masked by synthesis of this peptide. The best way to further investigate this NPY-
induced release of ET-1 using immunofluorescence is to add an inhibitor of 
protein synthesis which then would unmask the real decrease in the intracellular 
density of ET-1 in LEECs. In addition, the results obtained in this study 
demonstrating the higher ET-1 secretory capacity of REECs as compared to 
LEECs are in accordance with those mentioned above and showing that only 
REECs were able to secrete NPY into the extracellular medium upon stimulation 
with 30 mM of KCL (SADER, 2002). The higher ET-1 secretory capacity of 
REECs could be due to the fact that these cells possess a higher density of [ET-1 ]; 
when compared to LEECs (JACQUES et al, 2005). This may suggest that the 
latter would need a longer sustained rise in the [Ca]; in order for them to 
accumulate enough ET-1 for accomplishing their basal functions and for secretion 
after that. 
The differences in the kinetics of ET-1 secretion induced by NPY at the 
various concentrations tested, as well as the difference in the secretory capacity of 
ET-1 between REECs and LEECs (a higher secretory capacity in REECs as 
compared to LEECs) serves, once again, to highlight the asymmetry constantly 
observed between the right and left ventricular EECs. This asymmetry suggests a 
difference in the contribution of these 2 types of cells to the regulation of 
cardiomyocyte function in the human heart. Hopefully, more information will be 
available in the near future about the physiological implication of such a 
seemingly-important asymmetry. 
4.3 Bimodality of the NPY-induced secretion of ET-1 in human 
REECs and LEECs 
Looking at our results using the 3 different NPY concentrations (10~15M, 
10~10M and 10"5M), it can be noticed in both REECs and LEECs that NPY has a 
stronger ET-1 secretory effect at 10~15M and 10~3M when compared to 10"10M. 
This suggests bimodality in NPY's secretory effect on ET-1 with a high-affinity 
peak occurring at femtomolar concentrations (1CT M) and a low-affinity peak at 
micromolar concentrations (10 \xM or 1CTM). The presence of two peaks, one at 
very low and the other at very high concentrations, indicates that NPY is a potent 
ET-1 secretagoque from human EECs and that it can induce the secretion of the 
latter over a wide concentration range. This means that NPY, at a concentration 
close to the normal circulating level, can induce ET-1 release thus playing an 
important role in the regulation of the basal release of this peptide under 
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physiological conditions. On the other hand, it also means that NPY can regulate 
the release of ET-1 in pathological conditions including those with high 
sympathetic activity induced by stress, ischemia or injury (ZUKOWSKA-
GROJEC et al, 1988; SMIALOWSKA and BAJKOWSKA, 1997; LEE et al, 
2003; ZUKOWSKA et al, 2003). It seems that such a bimodal mode of action is 
not uncommon with NPY in other cell types. Low femtomolar doses of NPY 
suppressed gastric function, whereas higher picomolar doses activated it (CHEN 
and ROGERS, 1997; CHEN et al, 1997). In addition, both the mitogenic 
(ZUKOWSKA-GROJEC et al, 1998a; PONS et al, 2003; PONS et al, 2004) and 
the angiogenic (ZUKOWSKA-GROJEC et al, 1998b; MOVAFAGH et al, 2006) 
effects of NPY on vascular smooth muscle cells and human umbilical vein 
endothelial cells, respectively, were reported to be bimodal. In both cases, the 
NPY effect had a high-affinity peak at picomolar and a low-affinity peak at 
nanomolar concentrations. Several hypotheses were proposed for NPY's bimodal 
mitogenic response. The authors suggested that this bimodality is due to the 
participation of more than one receptor; and indeed, when they used specific NPY 
receptor antagonists, they showed that both the Yi and Y5 receptors were 
implicated in the growth promoting effect of NPY on VSMCs. They proposed that 
this bimodality could be due to VSMCs expressing the Yi and Y5 receptors in 2 
different states, with either high (pM) or low (nM) affinity. Then, based on 
previous data showing that upon agonist stimulation, many GPCRs display a 
decreased sensitivity (desensitization) to further activation by that agonist through 
receptor phosphorylation or endocytosis (BOHM et al, 1997), and based on 
evidence that the Yi receptor undergoes rapid internalization and recycling 
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through clathrin-coated pits upon activation by NPY (GICQUIAUX et al, 2002), 
the authors proposed another explanation for NPY's bimodality. They suggested 
that upon activation of the NPY receptors with picomolar concentrations of NPY, 
there is rapid internalization of the high-affinity receptors. The desensitization and 
disappearance of the latter from the plasma membrane would then lead to 
decreased responsiveness to NPY at 10"10M. While the high-affinity receptors are 
internalized, increasing the concentration of NPY to nanomolar levels would serve 
to stimulate the low-affinity receptors thus producing the second peak in NPY's 
mitogenic response (PONS et al, 2003). The same concept can probably be used 
to explain the bimodality obtained in our results regarding NPY's secretory effect 
on ET-1 with the difference being the concentrations at which we are observing 
the 2 peaks (10"Li and 10"5M in our study compared to 10"12 and 10"8M in the 
above-mentioned study). The third hypothesis proposed by Pons et al. to explain 
NPY's bimodal mitogenic response was related to the highly specific protease, 
dipeptidyl peptidase IV (DPP IV), which cleaves NPYi_36 into NPYv36, a peptide 
that loses activity at the Y] receptor and binds instead to the Y2 and Y5 receptors 
(MENTLEIN et al, 1993). So, the authors proposed that the above-mentioned 
enzyme can contribute to the bimodal response by cleaving NPY, thus affecting 
the affinities of different NPY receptors and shifting the activation from one 
receptor subtype to another. In other words, they suggested that increased DPP IV 
activity at NPY concentrations in between the 2 observed peaks, may serve to 
decrease the responsiveness at the Yi receptor to NPY stimulation and shift it 
instead to the Ys receptor, hence producing a bimodal proliferative effect (PONS 
et al, 2003). Since the presence of this protease was demonstrated in the 
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endothelium (LOJDA, 1979), and more particularly in human endothelial cells 
from the umbilical vein (ZUKOWSKA-GROJEC et al, 1998b), then it can not be 
excluded that our model of human endocardial endothelial cells also contains this 
enzyme, which makes this third hypothesis by Pons et al. also valid for explaining 
the bimodality that we observe in NPY's secretory effect on ET-1 in human EECs. 
Other hypotheses which the authors proposed for NPY's bimodal mitogenic 
response were differential coupling of the NPY receptors to different G proteins 
(i.e. other than GO at different concentrations of NPY thus leading to a bimodal 
response, or formation of heterodimers with GPCRs from another receptor family 
leading to alteration of receptor properties and formation of high or low affinity 
NPY proliferative receptor states (PONS et al, 2003). In fact, growing evidence is 
demonstrating that GPCRs from different families can form heterodimers resulting 
in modification of the properties and functions of the respective receptors (DEVI, 
2001; JORDAN et al, 2001). Following the same concept, and since we are 
investigating the existence of a crosstalk between the NPY and the ET-1 systems 
(the receptors of both of which belong to the GPCR family), we cannot exclude 
the possibility that, upon activation, their respective receptors may form 
heterodimer complexes resulting in the observed bimodal effect of NPY on the 
secretion of ET-1. 
As mentioned earlier, NPY was demonstrated to have an angiogenic effect 
in human umbilical vein endothelial cells which, once again, showed bimodality in 
each of its 3 steps, namely migration, proliferation and differentiation 
(MOVAFAGH et al, 2006). The authors proposed in this case that the 2 peaks 
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observed in NPY's angiogenic effect on the endothelium is due to the formation of 
NPY receptor oligomers of the Y,, Y2 and Y5 subtypes: heterotrimers for 
migration, heterodimers for proliferation and monomers for differentiation. Not 
only this, but they speculated that these oligomers form a part of larger complexes 
including other receptors, enzymes and receptor tyrosine kinases, whereby the 
peaks of NPY-induced angiogenesis correspond to the oligomeric state of the NPY 
receptors, and the valleys could correspond to either desensitization, dissociation 
of the oligomer or a transitional state (MOVAFAGH et al, 2006). It is worth 
mentioning that NPY receptor dimerization has been observed and reported before 
in the literature (for more details refer to (HOLLIDAY et al, 2004; MOVAFAGH 
et al, 2006)). Once again, we cannot exclude the possibility that NPY receptor 
oligomerization could be implicated in the bimodality observed in the NPY-
induced secretion of ET-1 at the level of human EECs. 
4.4 The tuning and sensory roles of LEECs and REECs 
Going back to the bimodality that we observed in NPY's secretory effect 
on ET-1 in human EECs, and as mentioned earlier, NPY at 10"'°M seemed to have 
a lower secretory capacity of ET-1 as compared to 10"15 and 10"5M. In fact, at the 
level of LEECs, a concentration of 10"10M NPY caused no decrease in the 
intracellular density of ET-1, suggesting that there was no release of ET-1 at this 
specific concentration. This absence of NPY-induced ET-1 secretion by 10"' M of 
NPY in LEECs may serve as a protection against increasing circulating arterial 
NPY, especially since such a concentration of NPY (10"10M) is considered to be in 
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the pathological range. In fact, elevated NPY concentrations are reported in cases 
of hypertension and high plasma NPY immunoreactivity was detected in patients 
with acute myocardial ischemia (ULLMAN et ai, 1994a) and congestive heart 
failure (ULLMAN et ai, 1994b). Moreover, ET-1 is also known to be involved in 
cardiac pathophysiological states, for the production of ET-1 was reported to be 
increased in cases of acute myocardial ischemia and myocardial infarction (SHAH 
et ai, 1996). Increased plasma ET-1 was also observed in cardiac failure and 
seems to be of bad prognosis in congestive heart failure [reviewed in 
(KURUVILLA and KARTHA, 2003)j. Both NPY and ET-1 are also hypertrophic 
factors for the cardiac muscle (reviewed in sections 1.2.2 and 1.3.2 of the chapter 
'Introduction', respectively). Based on all of the above-mentioned data, and since 
we can not exclude the possibility that ET-1, when released from EECs upon 
stimulation with NPY, can in its turn induce the release of NPY, then it can be said 
that the absence of ET-1 secretion from LEECs by 10 10M of NPY is of great 
physiological significance and may serve to prevent the exacerbation of any given 
cardiac pathological condition. Furthermore, this stimulatory effect of NPY at 
certain concentrations on ET-1 secretion by arterial EECs and inhibitory at other 
concentrations, may explain the role that this type of cells play as a tuning device 
for the level of circulating ET-1. NPY is therefore a controller of the tuning system 
of ET-1 in the arterial circulating blood. 
Speaking of the tuning role of endocardial endothelial cells leads us to talk 
as well about their sensory role. Having a unique position at the interface between 
the circulating blood on one hand and the myocardium on the other, and at the 
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entrance and exit of the pulmonary circulation allows the endocardial endothelium 
to play a very important role as the sensor device of the heart, if not the entire 
cardiovascular system (BRUTSAERT, 2003). In addition, the morphological as 
well as the electrochemical features that it possesses are consistent with such a 
role. Furthermore, being exposed to 100% of the circulating blood at least once 
every 2 minutes renders it a very important source of blood-borne factors, such as 
endothelial enzymes and cardioactive mediators, as well as an important site in the 
endothelial system where the overall composition of the blood can be altered, 
adjusted or normalized (BRUTSAERT, 2003). In other words, the endocardial 
endothelium can tune the composition of the circulating blood. In fact, and as 
mentioned in section 1.1.3 of the chapter 'Introduction', it has been proposed that 
in the sensor system composed of right and left endocardial endothelial cells, it is 
the role of the right endocardial endothelium to sense variations in the composition 
of the incoming blood, which are then adjusted or normalized by the left 
endocardial endothelium (fine tuning). The adjusted and stabilized blood is then 
optimally-delivered to the rest of the body. 
To best illustrate the sensor and tuning functions of REECs and LEECs, 
respectively, we can use the results obtained in this study. Our results showed that 
REECs seem to possess a much higher secretory capacity of ET-1 when compared 
to LEECs. It can thus be speculated that the venous blood arriving at the right 
chambers of the heart is low in ET-1, due to clearance or uptake or degradation in 
the peripheral organs. It is worth mentioning that clearance of ET-1 has been 
reported to take place in the splanchnic and renal vascular beds which represent 
very important and efficient clearance sites for ET-1. Moreover, uptake of ET-1 
occurs through its binding to cell surface receptors, which are then internalized in 
to the cell where degradation can take place [for more details refer to the review by 
(GRAY and WEBB, 1996)1. So upon contact of the venous blood with the right 
endocardial endothelium, we speculate that REECs will sense the low level of ET-
1 and will, as a result, release this peptide into the circulation. Then LEECs would 
adjust the level of circulating ET-1 through uptake for example. This could 
probably explain the higher secretory capacity of REECs as compared to LEECs 
which seem to have more of a tuning role for the circulating arterial ET-1. 
4.5 Role of the NPY receptors, Y1? Y2 and Y5 in the NPY-induced 
secretion of ET-1 at the level of human REECs and LEECs 
After demonstrating, in the first objective of this study, that NPY is able to 
induce the secretion of ET-1 from human endocardial endothelial cells, we 
wanted, as a second objective to explore if this NPY-induced secretion of ET-1 is 
mediated by the Yi and/or Y2 receptor(s). As previously mentioned, our group has 
recently demonstrated the presence of both these receptors at the level of 20-week -
old right and left ventricular EECs, with a higher density at the level of the nucleus 
as compared to the cytosol (SADER, 2002; PERREAULT, 2004). At the level of 
REECs, blockade of the Yi receptor did not have any effect on the NPY-induced 
decrease of the ET-1 intracellular density. This suggested that the Y| receptor is 
perhaps not implicated in the NPY-induced secretory effect on ET-1 in this type of 
cells. In order to confirm the results obtained by indirect immunofluorescence, we 
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performed ELISA; the results of which revealed that NPY elicited a rise in the 
extracellular concentration of ET-1 even after blockade of the Y] receptor. These 
results clearly suggested that the Yi receptor is not implicated in the secretion of 
ET-1 induced by NPY at the level of REECs. These results were surprising 
especially since activation of this receptor subtype was reported by our group to 
induce, in addition to the Y2 receptor, an increase in the intracellular calcium level 
in human REECs (SADER, 2002; JACQUES et ah, 2003b). This suggests that the 
secretion of ET-1 induced by NPY in REECs is not only due to the increase of the 
intracellular calcium level and/or the increase of intracellular calcium via Yi 
receptor activation is not sufficient to promote ET-1 release and that Y2 receptor 
activation is necessary. Indeed, blockade of the Y2 receptor in REECs resulted in 
no decrease of the fluorescence intensity of ET-1 after stimulation with NPY and 
was able to abolish the NPY-induced increase in the extracellular level of ET-1. 
These results clearly show that the Y2 receptor is indeed implicated in mediating 
the secretory effect of NPY on ET-1 at the level of human REECs. 
It is well known in the literature that the Yi receptor is the main receptor 
present in blood vessels and it is found in the heart as well. So it was 
conventionally thought that this receptor is the major subtype implicated in 
peripheral cardiovascular control. Our results, therefore, are unique since they 
show that the Yj receptor is not the main and/or major pathway by which NPY 
exerts its physiological and pathological actions in the cardiovascular system, but 
that the Y2 receptor pathway is highly and equally important. In addition, they 
show for the first time that Y2 receptor activation is implicated in the NPY-
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induced excitation-secretion coupling which could affect not only the contractility 
of the subjacent ventricular cardiomyocytes, but also contribute to the regulation 
of the normal functioning of the human heart. 
In contrast to the results obtained in REECs, our results in LEECs 
demonstrated that neither the single block of the Yi or Y2 receptor had any 
influence on the NPY-induced release of ET-1. Therefore, it is only logical to 
suggest that other NPY receptors, such as the Y5 receptor could be implicated in 
the above-mentioned effect. These results are similar to those reported by our 
group for the NPY-induced increase in the intracellular calcium level in LEECs 
which was also attributed to possible implication of Ys receptor activation. Such 
results highlight once again the differences between REECs and LEECs and 
confirm to us that a generalization concerning EEC function can never really be 
drawn. Furthermore, they suggest that not only the Y2 receptor is implicated in the 
phenomenon of excitation-secretion coupling in EECs (as was observed in 
REECs) but that the participation of the Y5 receptor is highly probable as well. 
This difference between right and left ventricular EECs regarding the excitation-
secretion coupling response to NPY could, therefore, be due, at least in part, to the 
presence or absence and/or differential density of the Y2 versus Y5 receptor. 
It is worth mentioning that we have not yet attempted to explore the 
presence of the Y5 receptor in EECs due to the unavailability of reliable 
antibodies, but this is certainly an issue that should be addressed in the future 
especially since a limited number of studies have reported the presence of this 
receptor in the heart as well as the blood vessels (BOROWSKY et ah, 1998; 
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PELLIEUX et al, 2000; PONS et al, 2003). In fact, in the study by Pellieux et al 
which was conducted using cardiac cells isolated from mice ventricles, Y5 receptor 
expression was readily detected in cardiomyocytes as well as non-myocyte cells 
(PELLIEUX et al, 2000). Such cardiac non-myocyte cells could possibly be 
endocardial endothelial cells lining the ventricles from which these cardiac cells 
were isolated. 
Before moving on to investigate the implication of the Ys receptor in the 
NPY-induced secretion of ET-1 in human EECs, we thought of using a cocktail of 
both the Yi and Y2 receptor antagonists at the same time (i.e. double-blockade of 
the Yi and Y2 receptors) with the aim of seeing if their combined application 
produces a different effect than the single application of each at a time. This 
phenomenon is actually not uncommon with the NPY receptors for it has been 
previously reported by the group of Pons et al. when studying the mitogenic effect 
of NPY in VSMCs. In these cells, double blockade of the Yi and Y5 receptors had 
a different result on NPY's mitogenic action in VSMCs as compared to each 
antagonist being used alone (PONS et al, 2003; KUO et al, 2007). 
At the level of REECs, the combined application of Yi and Y2 receptor 
antagonists was able to abolish the effect of NPY on the decrease of ET-1 
fluorescence intensity and on the increase in the extracellular level of ET-1. In 
other words, double blockade of the Yi and Y2 receptors reversed the effect of 
NPY on the release of ET-1 from REECs, which is basically the same effect that 
the Y2 receptor antagonist had in this type of cells. This actually confirms or 
endorses the role of the Y2 receptor in the NPY-induced secretion of ET-1 from 
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REECs. On the other hand, blockade of the Y5 receptor partially inhibited the 
release of ET-1 induced by NPY at the level of REECs. This suggests, therefore, 
that the Ys receptor contributes, in part, to the NPY-induced release of ET-1 in this 
type of cells. 
At the level of LEECs, and unlike what was observed upon single blockade 
of each of the Yi and Y2 receptors, double blockade of these 2 receptors 
completely abolished the effect of NPY on the secretion of ET-1. To better 
understand these results, we proceeded by using a selective Y5 receptor antagonist 
to block this receptor. Blockade of the Y5 receptor was also able to completely 
inhibit the NPY-induced release of ET-1 from human LEECs. In light of the 
above-mentioned results, it seemed to us that the Y5 receptor is mediating the 
whole effect of the NPY-induced release of ET-1 from LEECs, since its blockade 
completely reversed the NPY effect, whereas the single blockade of the Yi and Y2 
receptors produced no change in the secretion of ET-1 induced by NPY. 
Furthermore, we suggest that since neither the Yi nor the Y2 receptor antagonist 
alone had any effect in LEECs on the release of ET-1 elicited by NPY, but their 
combined application inhibited the aforementioned response, and since the Y5 
receptor seems to mediate the full effect of NPY in LEECs, thus it is logical to 
speculate that the Yi and/or Y2 receptors can be considered as a physiological Y5 
agonist. 
The Yj and Y2 receptors seem to have a positive cooperativity with the Y5 
receptor, where upon activation of the Yi or Y2 receptor by NPY, this leads to 
increased affinity of the Y5 receptor to NPY. Therefore, double-blockade of the Y] 
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and Y2 receptors will decrease the affinity of the Y5 receptor to NPY, and thus the 
effect observed will be similar to antagonist blockade. This possibly explains why 
upon double-blockade of the Y1 and Y2 receptors, there was a reversal for the 
NPY-induced release of ET-1 in LEECs. In fact, this cooperativity that we 
proposed between the Yi, Y2 and Y5 receptors could be explained by the fact that 
the Y5 receptor gene is colocalized with the Yi and Y2 receptor genes on the 
human chromosome 4q31-32 (PEDRAZZINI et ai, 2003; BERGLUND et ah, 
2003), and that it shares the same promoter with the Yi receptor gene (HERZOG 
et al, 1997). So it is possible that these 3 receptors share common regulatory 
elements (NAVEILHAN et ai, 1998). In 1998, the group of Borowsky et al. 
suggested that the Yi and Ys receptors could be in fact coregulated (BOROWSKY 
et al, 1998). Moreover, the Y5 receptor shares some roles with the Yi and Y2 
receptors in the brain, such as the role in the stimulation of food intake and in 
epilepsy (BOUALI et al, 1995; DUHAULT et ai, 2000; JINDE et ai, 2002). In 
vascular smooth muscle cells, both the Yi and Ys receptors seem to be implicated 
in the mitogenic response to NPY in vitro as well as in vivo. In a rat sprouting 
assay and in human umbilical vein endothelial cells, it is the Y2 and Ys receptors 
that seem to participate in the angiogenic response to NPY. In addition, the group 
of Movafagh et al, suggested in 2006 that NPY-induced angiogenesis in 
endothelial cells requires the participation of Yi, Y2 and Y5 receptor subtypes, with 
the Yi receptor acting as an enhancer (MOVAFAGH et ai, 2006). 
This new and important role of the Y5 receptor in mediating the NPY-
induced secretion of ET-1 in left ventricular EECs is consistent with the reports 
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available in the literature about its implication in cardiac hypertrophy (PELLIEUX 
et ai, 2000; BELL et ai, 2002). This is because ET-1, similar to NPY, is known to 
be a potent hypertrophic factor of the heart (reviewed in section 1.3.2 of the 
chapter 'Introduction'), so it is possible that NPY mediates its hypertrophic action 
on the myocardium, in part via its induction of ET-1 release from endocardial 
endothelial cells. The same phenomenon was reported for Ang II, for in the heart, 
it has been demonstrated that the positive inotropic effect of Ang II, depends to a 
large extent, on ETA receptor activation (CASTRO-CHAVES et ai, 2006). 
Moreover, Ang II induced ET-1 gene expression and release in cardiomyocytes, an 
effect which seems to be essential for mediating the cardiac hypertrophic effects of 
AngII(IMAIefa/. , 1992; ITO et a/., 1993; ROSSI et ai, 1999). 
Our results for this part, therefore, show that not only the Y2 receptor 
pathway is important for excitation-secretion coupling in endocardial endothelial 
cells, but that the Y5 receptor seems to be equally important. 
4.6 Role of the ET-1 receptors, ETA and ETB , in the NPY-induced 
secretion of ET-1 at the level of human REECs and LEECs 
In the last objective of this study, we wanted to investigate whether the 
secreted ET-1 due to NPY stimulation of EECs contributes to its own release via 
activation of the ETA and/or ETB receptor(s). So we treated REECs and LEECs 
with NPY in the presence of either an ETA or an ETB selective antagonist. At the 
level of REECs, blockade of the ETA receptor partially inhibited the effect of NPY 
on the secretion of ET-1. This suggests that the secreted ET-1 by NPY contributes, 
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in part, to its own secretion via activation of the ETA receptor. However, Y2 
receptor blockade completely inhibited the NPY-induced release of ET-1 in 
REECs, whereas ETA receptor blockade partially inhibited this release. Therefore, 
it can be suggested that a part of the Y2-mediated effect on the secretion of ET-1 in 
REECs is due to the released ET-1-mediated activation of the ETA receptor. 
Blockade of the ETB receptor followed by stimulation of REECs with NPY was 
able to abolish the release of ET-1 from these cells, suggesting the contribution of 
the ET-1 released by NPY to its own secretion not only by activation of the ETA 
receptor, but by activation of the ETB receptor as well. On the other hand, and in 
contrast to what was observed in REECs, neither blockade of the ETA nor 
blockade of the ETB receptor had any effect on the NPY-induced release of ET-1 
in LEECs. It seems therefore, that the ET-1 secreted as a result of LEEC 
stimulation with NPY is not contributing to its own further release. 
It is possible that the presence of an effect for the ETA and ETB receptor 
antagonists on the NPY-induced release of ET-1 at the level of human REECs is 
due to the high capacity of ET-1 secretion that this type of cells possesses and that 
was demonstrated by our results in this study. In other words, the level of ET-1 
secreted by REECs as a result of NPY stimulation seems to be sufficient to 
activate the ETA and ETB receptors on these cells resulting in their contribution in 
part to the NPY-induced-ET-l-stimulated-ET-1 release. However, the absence of 
an effect of both the ETA and ETB receptor antagonists on the NPY-induced ET-1 
secretion from LEECs could perhaps be explained by the lower ET-1 secretory 
capacity of these cells when compared to REECs. In other words, and by analogy 
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to what was said above for REECs, the level of ET-1 secreted by LEECs as a 
result of NPY stimulation does not seem to be sufficient to activate the ETA or ETB 
receptor. 
The contribution or the influence which ET-1 has on its own generation 
and release has been investigated previously by several other groups, but it seems 
that the data about it is still debatable. The group of Evans et al. in 2003, using 
human aortic endothelial cells, showed that treatment of the aforementioned cells 
with ET-1 increased the number of cells secreting ET-1 itself. This effect of ET-1 
on its own release seemed to be mediated by the ETB receptor (EVANS et al, 
2003). Hassellblatt et al. showed that neither basal nor stimulated ET-1 levels in 
astrocyte media were influenced by ETA or ETB antagonists alone, but were 
increased by the combined application of both (HASSELBLATT et al, 1998). In 
another recent study by Peled et al, it was demonstrated that ETB, but not ETA, 
receptor blockade increased preproET-1 transcription both in vivo and in vitro, 
with bovine aortic endothelial cells being used in the latter case (PELED et al, 
2006). Similarly, Sanchez et al found an increase in the ET-1 mRNA levels 
following ETB receptor blockade (SANCHEZ et al, 2002). On the other hand, 
Ozaki et al. showed that the expression of preproET-1 mRNA was unaffected by 
the ETB receptor antagonist, BQ788 (OZAKI et al, 1995). 
It is worth mentioning that similar to the experiments that were conducted 
in this study combining the application of the Yi and Y2 receptor antagonists and 
which produced different results than the single blockade of either one, combined 
application of the ETA and ETB receptor antagonists (i.e. double blockade of the 
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ETA and ETB receptors) should definitely be pursued in the future in order to better 
understand this phenomenon of NPY-induced-ET-l-stimulated-ET-1 release at the 
level of EECs. 
4.7 Summary and general conclusion 
As a summary, our results showed that: 1) NPY induces the secretion of 
ET-1 from right and left ventricular EECs in a dose- and time-dependent fashion; 
2) right ventricular EECs have a higher ET-1 secretory capacity when compared to 
left ventricular EECs; 3) in right ventricular EECs, the NPY-induced release of 
ET-1 seems to be primarily due to Yi receptor activation, with the subsequent 
activation of the ETA and ETB receptors by the released ET-1. The Y5 receptor 
seems to contribute as well to the secretory effect of NPY on ET-1; 4) however, in 
left ventricular EECs, the NPY-evoked secretion of ET-1 seems to be mainly the 
result of Y5 receptor activation by NPY; 5) the secretory process is, therefore, 
different between human right and left ventricular EECs. 
In conclusion, the results obtained in this study clearly demonstrate that a 
dialogue indeed exists between the systems of NPY and ET-1 at the level of 
human endocardial endothelial cells, since these cells, whether isolated from the 
right or the left ventricle, secrete ET-1 upon stimulation with NPY. The existence 
of interactions or crosstalk between two cardioactive mediators is not uncommon 
at all. As was previously reviewed in section 1.4 of the chapter 'Introduction', 
evidence in the literature about complex interactions between the different 
vasoconstrictors and vasodilators has become plentiful, particularly reports about 
the interactions between ET-1, Angll and NO at the level of the heart and blood 
vessels. Angll is known to stimulate the production and release of ET-1, whereas 
NO has been reported to inhibit it. On the other hand, ET-1 was demonstrated to 
elicit the release of NO. However, there are no reports, to our knowledge so far, 
showing that a dialogue exists between the systems of NPY and ET-1, be it in the 
heart or blood vessels. To be accurate, Hoang et al. in the year 2002 investigated 
the role of ET-1 on the evoked release of NPY from sympathetic neurons using a 
perfused rat mesenteric arterial bed. He showed that ET-1 was able to attenuate 
NPY release, upon high frequency nerve stimulation. The ET-1-induced inhibition 
of NPY appeared to be mediated by the ETB receptor (HOANG et al., 2002). So 
our results are unique in that they show, for the first time, that a crosstalk can and 
does exist between these 2 peptides in the cardiovascular system, and particularly 
in the endothelial cells that line the ventricular cavities of the human heart. The 
existence of such crosstalk in the endocardial endothelium, which is known for its 
very close proximity to the underlying myocardium, serves to endorse the 
important and rather indispensable role that these cells play in regulating cardiac 
growth, contractile performance and rhythmicity (BRUTSAERT, 2003). 
Recently, results obtained by our group have demonstrated that hEECs are 
able to secrete NPY into the extracellular medium and that this peptide can induce 
an increase in the [Ca]; of these cells (JACQUES et al., 2003b). In light of these 
results and those obtained in this study, we can speculate that the released NPY 
can then act in a paracrine fashion on the subjacent cardiomyocytes, or in an 
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autocrine fashion on EECs themselves to maintain its own secretion and/or induce 
the release of other peptides such as ET-1 (JACQUES and ABDEL-SAMAD, 
2007). Indeed, our results in this study show that NPY can induce the release of 
ET-1 from these cells. Similarly, the released ET-1 can further stimulate its own 
release via activation of its receptors, ETA and ETR on EECs (our results have also 
demonstrated the ability of ET-1 to contribute to its own release in EECs) or the 
release of NPY itself and this should be verified in the future. The luminal 
secretion by EECs of both these peptides into the ventricular cavity may affect 
their arterial circulating levels, whereas their abluminal secretion into the 
subendocardial space or the extracellular matrix located between EECs and the 
underlying myocardium would certainly contribute to normal functioning of the 
heart (ABDEL-SAMAD et ai, 2007). Furthermore, overstimulation of NPY or 
ET-1 secretion by EECs may lead or contribute to abnormal heart function such as 
arrhythmia, hypertrophy and heart failure (JACQUES and ABDEL-SAMAD, 
2007; ABDEL-SAMAD et ai, 2007). In fact, the correlation between elevated 
plasma levels of NPY and ET-1 and cardiac pathophysiological states has been 
documented in the literature. Increased NPY concentrations were reported in cases 
of hypertension and high plasma NPY immunoreactivity was detected in patients 
with acute myocardial ischemia (ULLMAN et ah, 1994a) and congestive heart 
failure (ULLMAN et al., 1994b). In addition, the production of ET-1 was reported 
to be increased in cases of acute myocardial ischemia and myocardial infarction 
(SHAH et ai, 1996), and increased plasma ET-1 was also observed in cardiac 
failure and seems to be of bad prognosis in congestive heart failure (reviewed in 
(KURUVILLA and KARTHA, 2003)). EECs, therefore, may contribute to the 
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local as well as the systemic release of factors, which can affect not only the 
excitation-secretion coupling of EECs and the excitation-contraction coupling of 
cardiomyocytes (BRUTSAERT and ANDRJES, 1992; SHAH et al, 1996; 
JACQUES et al, 2003a; JACQUES et al, 2003b), but also the physiological and 
pathophysiological states of the underlying heart muscle. 
Our results also show for the first time that the Y2 and the Y5, but not the 
Y], receptors mediate NPY-induced excitation-secretion coupling in EECs. Thus, 
it is highly important to consider controlling ET-1 circulating level via blockade of 
Yo and/or Y5 receptor activation. In addition, since the ET-1 released by NPY is 
contributing further to its own release via activation of the ETA and ETB receptors, 
then it is highly possible that the actions of NPY are mediated, in part, via its 
induced secretion of ET-1 and consequently, ET-1 receptor activation. This should 
be pursued in the future because in that case, one would expect that both NPY and 
ET-1 receptor blockade can modulate, at least in part, both NPY and ET-1 actions 
in physiology and pathology. 
More studies should be done in the future to better elucidate and 
characterize the exact molecular processes and pathways that are mediating this 
NPY-induced release of ET-1 in endocardial endothelial cells especially since 
multiple receptors (NPY receptors YT and Y5, and ET-1 receptors ETA and ETB) 
seem to be involved. It has become increasingly apparent from data in the 
literature that receptor activation can result in much more complex patterns of 
signaling within cells than previously thought. There is considerable evidence, for 
example, that signaling through GPCRs that couple preferentially to a certain 
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signaling pathway can be modulated by inputs from GPCRs that couple to other 
pathways. Such crosstalk between receptors can result in loss of function at times, 
and gain or enhancement of function at others (WERRY et ai, 2003). The 
crosstalk between NPY receptors, which are mainly Gj/0 coupled receptors, and 
other GPCRs such as ai -adrenoceptors, which are Gq/ncoupled, and |3-
adrenoceptors has been reported in vascular smooth muscle cells (RACCHI et ai, 
1999; PONS et ai, 2003) and may also be true of other cell types. Such synergistic 
crosstalk results in the augmentation of physiological responses such as smooth 
muscle contraction (in the case of interaction between the NPY receptors and aj-
adrenoceptors) and mitogenesis (in the case of interaction between the NPY 
receptors and (3-adrenoceptors) (SELBIE and HILL, 1998; PONS et ai, 2003). 
Based on the results that we obtained in this study, a similar synergistic crosstalk 
could be taking place between the NPY receptors, Y2 and Y5, which are, as 
mentioned before, mainly G;/0 coupled receptors, and the ET-1 receptors, ETA and 
ETB, which couple, among others, to Gq/n proteins. This should be definitely 
further explored in the future because it could have important implications on the 
physiological and pathophysiological consequences of receptor activation, and 
thus, could provide novel targets for therapeutic interventions (WERRY et al., 
2003). 
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